ITEM 1. Business.
A. Hydrodynex, Inc. - Introduction and Business Strategy
Hydrodynex, Inc., a Nevada Corporation, was founded on May 12, 2006, for the purpose of acquiring an exclusive North American license for the marketing and distribution rights of an anodic oxidation water disinfection product commonly referred to as the AO-System® technology. The primary objective of our company has been to commercialize this technology in North America initially through direct sales in order to gain a substantial market penetration. Hydrodynex has developed a strategic business plan to introduce and market the AO-Systems® in North America. Hydrodynex believes that due to the innovative technology, the AO-Systems® has the potential to be very competitive in the commercial water disinfection and treatment market.
As a result of the research and development work beginning in 1985 and conducted by Hydrosystemtechnik GmbH, from whom we were granted an exclusive license for the anodic oxidation water disinfection product, substantial technological discoveries were made and a mechanized water disinfection unit was developed and improved which is collectively referred to as the AO-System®. Hydrosystemtechnik GmbH has developed and commercialized this innovative water purification and disinfection system and has been selling these units in the European market for the last 17 years. In 2002, advancements to include warm water systems were developed by Hydrosystemtechnik GmbH. Two U.S. patents have been granted to Hydrosystemtechnik GmbH covering the apparatus design of a water sterilization unit that uses the principals of anodic oxidation without adding chlorine compounds. Hydrosystemtechnik GmbH had, as of the end of 2011, sold and installed over 160 AO-Systems® units of eleven different models for projects in Europe and approximately 15 other countries worldwide.
The U.S. EPA and NSF International have partnered to form an Environmental Technology Verification (ETV) Protocol that most states require. No AO-System® has yet been sold or is installed in the U.S., Canada or Mexico, and no system can be sold in the U.S. without approval of the U.S. Environmental Protection Agency (EPA), based on testing that is done by an approved entity such as NSF International. In developing a testing strategy and timeline with NSF International (NSF), the co-developer with the EPA of the required ETV Protocol needed for sales approval, we have estimated that a month would be required to develop the protocol, that about six months would be needed for the ETV testing, and an additional two months would be needed for the report formulation. The following chart details the basic certification process. Once the application is submitted by our company, our test reactor is delivered to the NSF testing facility in Ann Arbor, Michigan, and payments are made to NSF to begin testing, the process detailed in the chart below will be carried out by NSF. At the end of the process, if successfully completed, the EPA and NSF both sign the final report which will be written by NSF.
- 5 -
CPM = Certification Project Manager
For water disinfection units that pertain to drinking water systems, a Standard 61 leeching test is required throughout the U.S. to determine if chemicals or compounds from the unit’s structure are leeched into the water. This Standard 61 testing protocol for leeched contaminants from the unit is much simpler than the ETV testing and can be concurrently done by NSF and is estimated to span two months. If we decide to enter the pool and bathing water system market, a Standard 50 testing must be undertaken to determine if adequate microbial eradication takes place in bathing water systems. Another regulation that is required by state certification programs is electrical safety and grounding testing, often done by Underwriter Laboratories (“UL”) or a similarly qualified entity. This type of approval is necessary for selling and installing any electrical device within the United States.
Hydrodynex is also considering other business sectors at this time and on June 18, 2014, we entered into a definitive Sixty (60) day Option to Purchase Assets Agreement to purchase all of the assets of Zoydan Games, Inc (“Zoydan”), a private company organized in the state of Washington on July 8, 2011. The agreement calls for this issuance of Forty Two Million (42,000,000) shares of restricted common stock to be issued to Zoydan, which will be exchanged for specific assets of Zoydan and subsequently disbursed to the existing shareholders of Zoydan. Zoydan Games, Inc. was organized as a card and board game design, development, publishing and specialty marketing company. The acquisition of the assets of Zoydan will be subject to a vote of our shareholders pursuant to a future special meeting of the shareholders. On July 24, 2014, the Company and Zoydan agreed to extend the option date to September 15, 2014 and the option has not been exercised.
B. Hydrodynex’ Exclusive Technology License Agreement
We entered into a Marketing, Distribution and License Agreement with Hydrosystemtechnik GmbH September 3, 2007. On August 30, 2008, we entered into an Amended Marketing, Distribution and License Agreement, or amended license agreement, with Hydrosystemtechnik, which has the same effective date as the original license agreement, September 3, 2007,
- 6 -
and supersedes the original license agreement. Under the amended license agreement, we were granted the right to sell water disinfection systems based on the AO-System® technology in all markets (except the dental market) in Canada, the United States, and Mexico on an exclusive basis for a period of three years after the effective date of the license agreement. The license was to remain exclusive subject to Hydrodynex meeting the following milestones: (a) leasing or purchasing an AO-System® prior to November 30, 2009, as extended by the licensor, and (b) obtaining, by March 3, 2010, verification and certification of the AO-System® technology by the U.S. EPA necessary for commercialization and selling water disinfection systems in whole or in part within the United States. Since we failed to meet all of these milestones, our licensor could change our license agreement to a non-exclusive license and could terminate the agreement at any time. Those items were not satisfied, but the licensor has not as of this time reduced the exclusive license to a non-exclusive status.
Specifically, to maintain the exclusivity of the license we were required achieve minimum annual sales volume of 100.000 EUR in each business year subsequent to the third anniversary year after the effective date (Sept. 3, 2007), which we did not reach. In addition, in order to maintain the exclusivity of the license, we were obligated to (a) make application to six states in the Western U.S. for certification of the AO-System® technology within 90 days after receiving the NSF and EPA verification, (b) sell, deliver and install at least one AO-System® in the U.S. in the two year exclusivity period following technology verification, and (c) we are required to demonstrate financial responsibility in the form of a bank credit line or equity funding of not less than $500,000 to accomplish the objectives necessary to retain the exclusivity of the license. None of these criteria has been met and will not be met due to the time that is needed for NSF and EPA verification and the lack of capital currently available to the company. We plan to re-negotiate the license agreement with Hydrosystemtechnik to get the exclusive rights extended, but that is a forward looking statement and we are not likely to be successful in such negotiations unless sufficient capital funding can be brought into Hydrodynex and reasonable terms can be reached with the licensor.
We plan to undertake to secure technology verification from NSF, an independent third party testing laboratory, accredited by the EPA, to legally sell AO-Systems® in the United States, but we have not initiated this process because we have yet to pay the remaining balance of 17,625 for the AO-System® test reactor unit to our licensor Hydrosystemtechnik. Once we have completed our payment for the test reactor unit we can arrange delivery of the unit to NSF in Ann Arbor, Michigan for testing. When we have sufficient funds to pay the remaining balance of the test unit, arrangements for payment and shipping to the U.S. of the test reactor unit will be made.
We were also required, beginning year three after the effective date, or September 3, 2009, to meet certain minimum annual sales targets, based on net purchase value, for sales of AO-System® products in the North American territory, which increase from 30,000 in year three to 500,000 in year six and thereafter, in order to maintain the exclusivity of the license. We have failed to meet the minimum annual sales targets in each year and the licensor, Hydrosystemtechnik GmbH, has the option to revert the license agreement to a non-exclusive marketing agreement at any time. We have paid two non-refundable license fees in the aggregate amount of 30,000, and a third license fee in the amount of 20,000 will be due upon certification and approval of the AO-Systems® by the US Environmental Protection Agency for commercial sales in the United States. We were also required to attain and maintain minimum annual sales volume of 500,000 in order to have the right to manufacture water disinfection systems based on the AO-System® technology and sell them in the licensed territory. If after September 3, 2011 we do not maintain minimum annual sales volume of 500,000 in any two consecutive years, the right to manufacture will expire automatically in the subsequent year. Since we will not meet that minimum required sales volume for 2012 and we are unlikely to meet that requirement for 2013 as well, unless we renegotiate this requirement with the licensor we will lose the right under the license agreement to manufacture AO-Systems®.. We are obligated to pay a royalty on the products actually assembled or manufactured and sold to third parties in the amount of 10% of the net selling price on all AO-Systems®. We are not obligated to pay a royalty on finished AO-Systems® purchased from Hydrosystemtechnik and resold. We are also obligated to pay fifty percent of the direct costs related to preparing and prosecution of patents and patent applications in the U.S., Canada or Mexico, including legal fees, filing fees maintenance fees and transaction costs, so long as the license agreement remains in effect.
The license agreement terminates after ten years, with an option by us to extend the license for an additional ten years on an exclusive basis, as long as the required minimum annual sales volume is maintained. The licensor, Hydrosystemtechnik GmbH, has the right to terminate the license agreement, after a notice and cure period, if we are in default of any obligation in the agreement, are adjudged bankrupt, become insolvent or similar events, or if we do not maintain a minimum annual sales volume of 30,000 in the third year and 100,000 in each business year subsequent to the third year after the effective date (which means meeting the 100,000 minimum annual sales volume for each year beginning September 3, 2010) which sales volume has not been reached for the third year and the agreement can be terminated at any time.
If we are able to make the remaining payment of 17,625 for the AO-System® from our licensor Hydrosystemtechnik, and if we can obtain EPA approval for our AO-System and successfully re-negotiate our license agreement, we plan to market, sell, install, and maintain specialized AO-Systems® on a retail basis pursuant to the license.
- 7 -
Stationary-type systems will be sold and installed in facilities such as hospitals, hotels, water cooling towers, swimming pools, etc. Transportable AO-Systems® and packaging units will be marketed to the U.S. military and other associations involved in the use of portable water treatment systems for emergency and non-emergency markets. Hydrodynex will purchase components on a wholesale basis from Hydrosystemtechnik to make, use, and sell specific water disinfection systems on a custom basis for it customers. Hydrodynex has the option to engage in future manufacturing of the AO-Systems® when it is deemed necessary and financially justifiable, if we do not lose that right due to not maintaining minimum annual sales volume of 500,000 in any two consecutive years.
Activities to date have been limited primarily to organization, initial capitalization, business and product research, producing marketing materials and a website, securing a marketing agreement, preparing a comprehensive business and operating plan, evaluating the regulatory requirements to sell water treatment systems in the U.S., Canada and Mexico, and undertaking a marketing feasibility study. Extensive research has been done on competing technologies and the water contaminants that most adversely affect water systems at the present time. Legionella bacteria protection is the strongest market Hydrodynex has identified because of its wide prevalence and the high percentage of death resulting from infection.
Our company is structured expressly as a marketing entity and therefore we do not currently engage in the design, development or manufacturing of products. In phase one of our multiphase marketing plan, subject to successful renegotiation of our license agreement, payment for and receipt of the AO-System® test reactor unit, and subsequently, receipt of approval from the EPA, of which there is no assurance, we intend to market and sell the AO-System®, a device that disinfects potable water systems and industrial water systems, under an OEM arrangement with our Licensor Hydrosystemtechnik, GmbH. To date, we have no revenues from operations. Our expenses consist of management activities and personnel costs. If necessary funding is obtained and approval to sell the units in North America, we intend to accomplish the following:
•
Establish effective marketing channels for our products through a network of distributors or dealers in selected markets.
•
Support revenue generation in these channels by effectively educating the end user and promoting the use of AO-Systems® as a means of assuring the delivery of safe, healthy water at low costs and eliminating the Legionella bacteria from existing buildings.
•
We intend to have Hydrosystemtechnik GmbH provide the AO-Systems® under a brand label to be determined.
•
We intend to register Hydrodynex as a company registered trademark.
In addition to the risk factors set forth herein, additional obstacles, which we may encounter in launching our business model, are as follows:
1. If we do launch planned marketing initiatives, our target market may not be receptive to our business and may not purchase our products.
2. Potential customers may not be willing to pay the price for our products.
3. Distributors and dealers may not continue to carry our products if we fail to meet their standards pursuant to our agreements with them.
4. We may be unable to establish new distributors or dealers in the balance of our marketing territory if our performance with those channels during our initial launch does not demonstrate a level of opportunity consistent with their standards.
The water treatment industry is a rapidly growing sector and a primary component of the world’s basic needs market. World demand forecasts for water treatment products, chemical and non-chemical, is projected to increase 6.4% per year to nearly $40 billion in 2011, according to “World Water Treatment Products,” a new study from The Freedonia Group, Inc. (2008). With over 20 large target industries benefiting from clean water, i.e.; food processing, water bottling, and swimming pools, and with an ever-present threat of water-borne diseases and other biohazard and inorganic aquatic health threats, along with mechanical corrosion issues, the clean water industry is paramount in importance to the U.S. and the rest of North America. Competing technologies currently on the market or under development, but none of them utilize the patented technological properties of advanced Anodic Oxidation that our AO-System® employs. Competing systems known as salt electrolysis machines use a more primitive form of anodic oxidation that requires salt to be added. Anodic oxidation is a broad term, simply referring to oxidant creation by an anode with electricity. As shown by the AO-System’s® two U.S. patents, #’s 5,439,576 and 5,395,492, our mode of anodic oxidation utilizes novel technology, with specialized electrode composition and advanced processes.
We have observed in news article releases that several lawsuits have been filed against U.S. facilities such as hospitals, hotels, retirement homes, and cooling towers, because people have gotten sick or died as a result of their water system uncleanliness. We have seen several outbreaks of water-borne illnesses in recent years in municipal, residential and rural water systems, including outbreaks of Cryptosporidium, E. coli, Pseudomonas, Norovirus, Echovirus, methicillin-
- 8 -
resistant Staphylococcus aureus, Giardia intestinalis, Shigella sonnei, etc. An estimated 1,400 people in the U.S. die each year from Pseudomonas in hospital water systems. The Center on Disease Control and Prevention (CDC) has estimated that up to 18,000 people each year in the U.S. are infected with water-borne Legionella bacteria, 25% of those estimated from Healthcare environments.
Legionnaires’ disease, caused by Legionella bacteria, is particularly dangerous and has already caused significant lawsuits against hospitals, such as the Good Samaritan Hospital of Los Angeles in 2003, where the disinfection processes used by the facility were insufficient in preventing death to immuno-suppressed patients. The AO-System’s® technology has been shown to permanently eliminate micro-organisms in water systems through its short and long-term oxidative effects. The AO-System® has been installed to provide a solution for several existing and previously infected water systems in closed circuits such as hot water systems in hospitals like the Vinzenz V. Paul Hospital in Rottweil Germany, the KKH Dorfen Hospital in Dorfen, Germany, and the KKH Prien Hospital in Prien, Germany. However, there exists many other commercial applications in facilities such as cooling towers and food processing plants that could benefit from our system providing protection as well as preventing expensive shut-down periods for cleaning. Being a new technical solution with more than 160 systems installed in 15 countries, the AO-System® has a good reputation and successful track record, as concluded by our company from contacting current owners of the AO-System®, such as Vinzenz von Paul Hospital in Rottweil, Germany, and Hotel Novotel in Munich, Germany. W e also reviewed positive facility water testing results from current clients such as Hotel Novatel in Munich, Germany, and the H.I.T. Haus industrial complex in Dachau, Germany.
The organism that is causing the greatest problems is the Legionella bacteria, the most dangerous and most prevalent water bio-contaminant in the market. Hydrodynex has learned about dozens of outbreaks in the U.S. and subsequent litigation resulting from those outbreaks. Legionnaire's, with an average fatality rate of 28%, is estimated by the Center of Disease Control to be responsible for up to 20,000 cases in the United States every year. About 35 percent of all cases are acquired in hospitals, where the death rate from infection can be as high as 40 percent, the CDC said. It is estimated by the U.S. Department of Labor Occupational Safety & Health Administration that in the United States there are between 10,000 and 50,000 cases of Legionnaires' disease each year. Because of these staggering numbers, Legionella is the number one focus of Hydrodynex at this time. The primary reason that hospitals have such a high degree of mortality is because many of the individuals in the hospitals have their immune systems compromised due to medication, surgery, chemotherapy, etc. This phenomenon is also seen in retirement homes. Below is a chart that has been constructed with data from a Legionella study that quantifies Legionella presence in a variety of topographical areas.
Strategy
We need to raise a minimum of $400,000 to implement and complete the first phase of our business plan, as well as to renegotiate the terms of our license agreement, if possible, to allow us to continue our business plan. There will be an addition requirement of $2,000,000 to complete the second phase of our business plan. There is no assurance that we will be successful in renegotiating our license agreement and not lose our exclusive or non-exclusive license agreement and there is no assurance of raising these funds and in the event were are successful, there is no assurance that the terms and conditions of
- 9 -
these funds will be in the best interest of our company or our shareholders. We do not have any arrangements for financing and we may not be able to find such financing if required. We will need to obtain additional financing to operate our business for the next twelve months, and if we do not, our business will fail. We will raise the capital necessary to fund our business through a private offering of our common stock or units consisting of common stock and stock purchase warrants. Obtaining additional financing would be subject to a number of factors, including investor acceptance of our business strategy, its technology and investor sentiment. These factors may adversely affect the timing, amount, terms, or conditions of any financing that we may obtain or make any additional financing unavailable to us.
Phase 1: Renegotiation of our License Agreement, Finalization of the Strategic Marketing Plan, initial start-up capital realization through a second private stock offering, pay for and receive delivery of the AO-System® test reactor unit, undertaking independent testing, securing EPA and State certification, and hiring/training sales and technical personnel.
Phase 2: Initiation of marketing and sales activities in selected markets in North America (U.S., Canada, and Mexico). Full scale commercialization of the AO-System®, including industrialization and after-sale service agreements, for the markets covered by Hydrodynex. As part of its effort to commercialize the AO-System®, Hydrodynex plans to offer mobile systems which may use a film pouch packaging system.
The objectives are:
(a) establish our product as the un-paralleled leader in water disinfection systems,
(b) enter and cover all market segments in the U.S., Canada, and Mexico.
(c) get the AO-System® required and mandated by local, state, and national insurance agencies and governments.
C. Hydrodynex Licensed Products
The AO-System® units that Hydrodynex plans to sell utilize a novel and patented advanced technology broadly known as Anodic Oxidation. The AO-System® delivers this technology with eleven different reactor unit models to a wide range of water volume parameters and applicable markets such as potable water systems in buildings, municipal water treatment plants, and cooling tower disinfection. The eleven different models have essentially only two variables in their parameters, a) ability to treat different water flow volumes, and b) ability to treat hot, cold, or both temperatures of water systems. Improved electrode composition, design configurations, and process tuning, which are characteristics described in the associated patents make this generation of AO-System® more advanced than other AO technologies developed over the past several decades. We feel that the due diligence information gathering we have performed on other current competing technologies shows that the AO-System® offers higher disinfection standards and we have found various shortcomings in competing technologies, as discussed below in Section E. When treating water for Legionella bacteria, conventional methods consisting of hyper-chlorination and super heat-flushing are generally known in the industry as temporary fixes and not permanent solutions. The AO-System® provides a viable technical solution to kill Legionella bacteria and maintain a safe water system environment.
Initially, Hydrodynex does not plan to produce any products or components; instead it plans to act as an exclusive master distributor of AO-Systems® in Canada, the United States, and Mexico, assuming that we can re-negotiate our license agreement. When and if the volume of sales warrants the setup of an assembly and manufacturing facility in North America, we plan to enter Phase II of our business plan and take on the responsibility of assembling and manufacturing the units by Hydrodynex or outsource the manufacturing to a reliable subcontractor here in the U.S. or another foreign country.
D. Description of Proprietary Technology
The AO-System® is generally installed as a point-of-entry device on warm and/or cold water systems. Water passes through a reactor chamber of the unit which contains specially engineered electrodes that produce oxidizing effects in the water as an electrical current is generated to pass from the cathodes to the anodes. Instrument observed water flow determines the amount of electrical current generated and the computer unit automatically controls the system. The system can bypass itself for regularly scheduled back-wash cleanings which prevent build-up on the electrodes and thereby increase the longevity of the system and its components.
Advanced Anodic Oxidation is an electrochemical in-situ sterilization process which produces deactivating (microbiocidal) oxidants directly from the water being treated. No chemical additives are necessary for the treatment. The water flows into the reactor from the bottom then up through the spaces between the electrodes, serving directly as an electrolyte. The deactivation (killing) of microorganisms such as bacteria, fungi, algae & viruses occurs predominantly
- 10 -
through oxidation in the anode boundary layer (due to short life absorbed oxidants), ultimately being optimized for maximum effectiveness. In operation with neutral pH, another dominant anode mechanisms can be verified, the creation of ozone, which is a strong oxidizing agent, and helps assist in bio-deactivation. A secondary oxidative effect is the synthesis of hypochlorous acid, a weak acid, but very strong long-life oxidizer that travels out into the distal piping network and disinfects the water and pipes and helps break down biofilm and mineral scaling.
Other benefits of the AO-System® include lowered energy consumption by the facility by not having to raise its warm water network above 55 degrees Celsius. Many places raise their water temperature up to 70 or even 80 degrees Celsius at night to combat problems they encounter, which results in the danger of scorching to consumers, highly increased pipe corrosion, and dramatically increased energy consumption. The AO-System® also partially softens water by increasing the solubility of common precipitates and removing solutes within the reactor. It also cleans existing pipe corrosion and breaks down scaling deposits. The cost of replacing a piping system in a building is a very expensive, lengthy, and invasive process.
E. Other Competing Technologies
Water treatment and purification systems with increasing complexity and effectiveness have been put into operation worldwide for a number of years. However, conventional mechanical and chemical purification processes, including hyperchlorination, heat flushing, copper/silver ionization, chlorine dioxide dosing, and other means have proven to be insufficient in preventing the distribution of diseases through this essential nutritional element that water represents, that is why a continuing and substantial number of water borne outbreaks and disease from potable water sources occur. Recognizing that special disinfection methods had to be developed to eliminate micro-organisms such as bacteria and viruses, heavy chlorination and other chemical treatments, and more recently UV and Ozone treatments, have been introduced. These processes, however, each include significant disadvantages to the AO-System®. Some, such as hyperchlorination, chlorine dioxide dosing, and salt electrolysis release hazardous byproducts like chlorates and chlorites. Some can only disinfect water that moves past a static disinfection zone in a pipe and has no residual or distal cleaning effect on bioslime within a system, such as in the case of UV light and Ozonation. Copper/Silver ionization only has a weak disinfection effect on the water and does not have a satisfactory killing rate of robust bio-contaminants like protozoa and Legionella bacteria.
F. Market Analysis and Competition
These facts lead to the belief that the Hydrodynex AO-System® process has the potential to replace most of the competing processes. However, the replacement will be gradual due to the fragmentation of the industry. Of over 40 companies currently competing in the water disinfection industry, we have found no evidence or data from our due diligence research that suggests that any one company has a U.S. market penetration of more than 10%. In our correspondence with several industry experts, we found no particular company or technology is a current front-runner and large market share holder in the water disinfection industry.
We believe that the AO-System® has the potential to be the market leader based on the belief that the system has few negative attributes, has dependable technology, and requires little maintenance. A mid-sized AO-System uses power for operation that is about equivalent to two microwave ovens. There can be traces of disinfection byproducts when a large amount of organic material is suspended in the water being treated. Because the created oxidants in the system clean lime scaling and existing corrosion, metal piping material can become thinner as the corroded layers are striped away by the oxidants.
Hydrodynex’ management believes that Hydrodynex’ main competitiveness is expected to be based on technological superiority and high disinfection efficacy, rather than price. Hydrodynex will be competing against companies with products it believes are less efficient and that are less expensive than the AO-System®. These companies are much larger than ours, have well established market reputations and have substantially more financial resources than our company. The main currently used disinfection systems are based on heat and chlorination (most common), and more recently, Copper/Silver ionization, chlorine dioxide, sodium electrolysis, UV light, and Ozone systems.
In the last few years, several companies have introduced a Copper/Silver Ionization process which was installed for testing in at least 16 hospitals in five states. This shows that there is indeed a viable market for more efficient disinfection systems. It should be noted that while that system is simpler than conventional systems, it has numerous deficiencies when compared to the AO-System®, such as heavy maintenance and monitoring requirements, as well as inferior disinfection efficacy as revealed in discussions between our company representatives and a water system specialist at UCLA Medical Center, which currently uses Copper/Silver Ionization onsite. Chlorine Dioxide is the other major competitor to our technology, but also has several deficiencies when compared with advanced Anodic Oxidation. Examples would be such things as harmful carcinogenic byproducts, large amounts of dangerous chemical dosing and inefficient Legionella
- 11 -
eradication. Research papers like the following show these chlorine dioxide inadequacies; “Point-of-care controls for nosocomial legionellosis combined with chlorine dioxide potable water decontamination: a two-year survey at a Welsh teaching hospital.” Journal of Hospital Infection, 2005 61(2): p. 100-106,
Electrolytic chlorinators have been seen entering the market recently, but the statistical effects of it on Legionella and Protozoa have not shown perfect results. Very recently, two more competing companies have marketed “photo-oxidation” and “Reticulated Electro-Catalytic Oxidation Reduction”, but information on these systems is limited and the validity of these systems is yet to be seen.
In management’s opinion and to its knowledge, at this point in time, there is no technology similar to advanced AO-Systems® available in the United States. However, the market resistance against new products and new technical solutions has to be overcome in order for the company to become successful and there is no assurance that this will happen. Potential customers may be unwilling to purchase from an under-funded development stage company such as ours that has no proven track record and is understaffed. But we believe that the need for our system is great and we can offer certain advantages, as high-lighted in the above section D.
The competitive situation may adversely affect Hydrodynex’ sales or capacity to retain or increase clientele or business. There are no assurances Hydrodynex will be able to successfully compete against these other competitors based on these factors. In order to compete with these other companies, Hydrodynex plans to attempt competitive pricing, above average customer service, high quality products and provide independent research and testing that will provide conclusive evidence that the AO-System® is the leading and best technology available. In addition to the technological advantages of the AO-System®, this system is very competitive when it comes to operation and maintenance costs and treatment cost per gallon of water.
We’ve estimated from speaking with competing technology companies that a 250,000 gallon/day Chlorine Dioxide system costs an average of $50,000, with a one year warranty, $400-$16,000 per month in chemicals, and $1,000 per month in maintenance. The costs for a Copper-Silver ionization machine ranges from $60,000 to $86,000, with expensive electrode replacement costs, short 1-3 year warranties, heavy maintenance, and around $15,000 per year in testing fees. Our warranties would be over the five year mark and much more attractive to consumers. The initial purchase price of our system could be higher than most competing systems, however our system will potentially be leased for this water volume for around $3,000 per month, and that is maintenance inclusive and will be very cost competitive when chemical cost, part replacement, unit life, and maintenance difficulty are factored in. Our system does not use dosing chemicals and will not require frequent part replacement.
G. Marketing and Sales
Once certification has been granted by the EPA, we intend to focus our sales and marketing program directly toward certain targets of opportunity. The most important targets are those where water safety is paramount; in facilities and industries where unhealthy people are exposed to additional disease and lives are being lost, where expensive and reputation tarnishing lawsuits are in abundance, and where other competing products are failing to properly address these issues. Four primary markets have been researched and evaluated by our management. These four areas are hospitals, hotels, military applications and applications for mobile disaster relief. Secondary marketing targets are water cooling towers, food processing facilities, retirement homes, spas, schools, industrial plants, public fountains, pools, water slide parks, cruise ships, etc.
We will attend trade shows and undertake a direct marketing program to key hospitals in the southwestern section of the U.S. Marketing efforts will initially be concentrated in the states of Nevada, Arizona, and California. Prospective customers and marketing targets include Good Samaritan hospital in Los Angeles, which recently weathered a Legionnaires’ disease lawsuit involving two deaths. The company is developing a comprehensive marketing brochure to define the differences between the AO-Systems® and other competing water treatment systems now available on the market. We have already created a website to begin educating the market about the AO-System®- www.HydroDynex.com.
Subject to receiving the necessary regulatory approvals from the EPA, we will develop all the appropriate technical brochures, presentations, marketing materials, upgrade of our website, and develop a sales team, we will initiate meeting with potential customers and attend key trade shows. We intend to use an integrated plan that includes a robust and informative web site, target advertising, trade shows and personal contact to establishments that have a reported history of problems related to Legionella. The identification of potential customer will be determined by a comprehensive analysis of the existing market. Hydrodynex plans to attend and/or participate in trade shows and do direct mailings and call on to potential clients as
- 12 -
its marketing strategy. Relationships with scientists, organizations, associations, insurance companies, government agencies and media will help in marketing the product.
Each target customer will receive comprehensive marketing communications that address the benefits from the purchase and use of the AO-System®. The marketing mission will be focused on educating the potential customer and providing information that relates to how the system is a unique technical solution that will eliminate the deadly virus of Legionella in hospitals, hotels, military applications, mobile disaster relief units, water cooling towers, food processing facilities, retirement homes, spas, schools, industrial plants, public fountains, pools, water slide parks, cruise ships, carwashes, auto plants using water cooling machinery, fountains, ice rinks, air-scrubbing plants, health-club showers, public pools, mines, schools, industrial air-cleaners, prisons, stadiums, homes, cruise ships, etc.
Hydrodynex will also look to present to building construction companies such as Ellerbe Becket and McCarthy Builders and invite them to infuse our systems into their new and old projects. Builders want their projects to be problem free and safe to the tenants, so an approach such as this should prove profitable.
H. Patents, Trademarks, and Copyrights
We are substantially dependent on the ability of Hydrosystemtechnik to obtain and maintain patents and proprietary rights for our product, and to avoid infringing the proprietary rights of others. We have interests in two patents issued by the United States Patent and Trademark Office. Additional patent applications may be forthcoming from ongoing research and development.
On September 3, 2007, we obtained an exclusive license in Canada, the United States and Mexico from Meinolf Schoeberl and Hydrosystemtechnik to any proprietary technology being developed by Hydrosystemtechnik involving advanced Anodic Oxidation water disinfection units in any markets but the dental market. Since we have failed to meet certain minimum annual sales targets under the license agreement, the licensor, Hydrosystemtechnik GmbH, has the option to revert the license agreement to a non-exclusive marketing agreement at any time.
Hydrosystemtechnik GmbH, is the owner of two U.S. patents, numbers 5,395,492 granted on March 7, 1995, and 5,439,576, granted August 8, 1995, both entitled “Apparatus for the Sterilization of Water”. Both patents describe innovative methods of sterilization of water using anodic oxidation. Anodic oxidation is a process of using anodes and cathodes inside a reactor chamber for the purpose of conducting high electrical current, which generates over-voltage with respect to oxygen generation, and generates chlorine equivalent oxidants. The reactor creates a significant amount of oxidants to sterilize the water, but does so in a way without adding chlorine.
We have not filed for any copyright or trademark protection to date.
I. Employees
The President, CEO, CFO, COO, VP, Treasurer, and Secretary of Hydrodynex, Jerod Edington, receives no monetary compensation and no employment or other compensation arrangement with our company. Mr. Edington is a part-time business consultant and works approximately five hours per week for the benefit of Hydrodynex.
J. Governmental Regulation
No AO-System® has yet been sold or is installed in the U.S., Canada or Mexico, and no system can be sold in the U.S. without approval of the U.S. Environmental Protection Agency (EPA), based on testing that is done by NSF International. The U.S. EPA and NSF International have partnered to form an Environmental Technology Verification (ETV) Protocol that most states require. In developing a testing strategy and timeline with NSF International (NSF), the co-developer with the EPA of the required Environmental Technology Verification (ETV) Protocol needed for sales approval, we have estimated that a month would be required to develop the protocol, that about six months would be needed for the ETV testing, and an additional two months would be needed for the report formulation.
For water disinfection units that pertain to drinking water systems, a Standard 61 leeching test is required throughout the U.S. to determine if chemicals or compounds from the unit’s structure are leeched into the water. A much simpler Standard 61 testing protocol for leeched contaminants from the unit can be concurrently done by NSF and is estimated to span two months. Standard 61 is not overseen directly by the EPA, but is required by individual states to allow products to be sold within their state. Any water treatment device that has “wetted parts”, or parts that come in direct contact with drinking water, must have those parts tested for acceptable levels of leeched contaminants into the drinking water. Specific parts are exposed
- 13 -
to different water temperatures and pH level variables for certain lengths of time to determine if any unacceptable levels of contaminants enter the water. Once Standard 61 testing is concluded, the tested unit category will earn the NSF 61 mark. Different volume flows can be bracketed so every specific size of disinfection unit does not have to be tested. All of our current models of AO-System® units will be encompassed in two bracketed categories, so only two particular models will need to be tested.
If we decide to enter the pool and bathing water system market, a Standard 50 testing must be undertaken to determine if adequate microbial eradication takes place. Each individual state governs its own regulations as related to water disinfection products and the ETV Protocol. California, for example, requires pre-approval of the testing protocol be used for the ETV laboratory testing of microbial eradication so that it meets their standards, and California also requires certain Standards to be met depending upon the use of the water disinfection unit, such as the aforementioned Standards 51 and 60. Other certain non-governmental agencies might also be required to inspect the units for adequacy on such things as seismic activity durability.
Another regulation that is required by state certification programs is electrical safety and grounding testing, often done by Underwriter Laboratories (“UL”). This type of approval is necessary for selling and installing any electrical device within the United States. Due to electrical components, motors, and wires, the AO-System® must undergo a thorough investigation by an accredited product safety laboratory such as UL for testing of equipment risk and certification. This process is estimated to take two months and could cost $25,000 or more.
ITEM 1A.
ITEM 1A. Risk Factors
Investing in our securities involves a high degree of risk. In addition to other information contained in this registration statement, prospective purchasers of the securities offered herby should consider carefully the following factors in evaluating Hydrodynex and its business.
The securities we are offering through this registration statement are speculative by nature and involve an extremely high degree of risk and should be purchased only by persons who can afford to lose their entire investment. We also caution prospective investors that the following risk factors could cause our actual future operating results to differ materially from those expressed in any forward looking statements, oral, written, made by or on behalf of us. In assessing these risks, we suggest that you also refer to other information contained in this registration statement, including our financial statements and related notes.
RISKS RELATED TO OUR COMPANY AND OUR INDUSTRY
We were unable to meet our milestone and minimum annual sales obligations under the Marketing, Distribution and License Agreement and we can lose the exclusivity of the license and the licensor could terminate the license agreement at any time.
Under our license agreement with our licensor Hydrosystemtechnik, we are required to meet a number of specific milestones by certain dates, which we have failed to achieve, and our license agreement can become non-exclusive, damaging our competitive situation, or the licensor could decide to terminate the agreement. We have currently not met any of our milestone obligations. In addition, we were required to meet certain minimum annual sales volumes based on net purchase value of sales for calendar years beginning in 2010. We were unable to meet those minimum annual sales volumes and our license can become non-exclusive and in addition, our licensor could terminate the agreement at any time by written notice because there are already existing defaults concerning obligations in the agreement and there are no actions that can be taken by us to reasonably require a cure notice from our licensor and a 30 day cure period as outlined in our agreement.
We must raise additional capital to make the required product purchase under our license agreement to our licensor.
Under our original license agreement with our licensor Hydrosystemtechnik, the license would remain exclusive subject to Hydrodynex leasing or purchasing an AO-System® prior to November 30, 2009. We have paid a 50% down payment, but we need to secure additional capital to cover the remaining 50% balance payment in the amount of 17,625 for the AO-System® test reactor unit from our licensor Hydrosystemtechnik. The licensor has the option at any time to revert our exclusive license agreement to non-exclusive status or to terminate the agreement completely.
We were unable to obtain approval from the Environmental Protection Agency to commercially sell the anodic oxidation water treatment/disinfection systems in the United States by March 3, 2010, therefore our license can revert to a non-exclusive license and our licensor could terminate the license agreement at any time.
- 14 -
Under the terms of our license agreement with our licensor Hydrosystemtechnik we were required to gain approval from the Environmental Protection Agency by March 3, 2010, thirty months after the effective date of our license agreement. The verification and certification process leading to such approval involves extensive testing and is an expensive process. We will have to raise additional capital to pay for the independent verification and certification process leading to approval. We have made contact with staff at NSF, gotten price quotes, and met with NSF representatives in person. We are currently attempting to raise capital through the sale of equity to pay for the balance owed on the test reactor that we have ordered from our licensor so that we can begin the testing process with NSF. We failed to meet the deadline for approval from the EPA for the AO System® water disinfection technology, and it is possible we will not be able to commercially sell it in the United States if our license becomes non-exclusive and our licensor terminates the amended license agreement which they can do by written notice at any time.
We must pay license fees, royalties, and purchase products using a different currency.
Fees and royalties to our licensor, as well as minimum annual sales targets and purchases from Licensor are all in Euros. We also purchase wholesale goods from our foreign licensor in Euros. Further weakening of the dollar could significantly increase our cost of goods, our fees payable under the license agreement, as well as the minimum annual sales targets we are required to meet.
If we are able to secure approval from the Environmental Protection Agency, we may not be able to establish sufficient sales and marketing capabilities in the U.S. or enter into agreements with third parties to sell and market any products due to our lack of experience in these areas, we may not be able to generate product revenue.
We do not currently have an organization for the sales, marketing and distribution of our product. In order to market any products, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. In addition, we have no experience in developing, training or managing a sales force and will incur substantial additional expenses in doing so. The cost of establishing and maintaining a sales force may exceed its cost effectiveness. Furthermore, we will compete with many companies that currently have extensive and well-funded marketing and sales operations. Our marketing and sales efforts may be unable to compete successfully against these companies. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable.
We would be initially dependent on third-party manufacturers, over whom we have limited control.
The manufacturing process of the AO-Systems® and any other ancillary replacement components would be initially been outsourced to the Licensor, pursuant to the terms of the existing License Agreement between Hydrodynex and Hydrosystemtechnik GmbH. The Licensor is dependant upon many third party vendors in Germany and other European countries to supply essential components, which are assembled and tested in the Licensor’s manufacturing facility in Germany. We do not have any manufacturing facilities and expect to rely upon Hydrosystemtechnik to properly manufacture our products. Our dependence upon a third party for the manufacture of our proposed products may adversely affect our profit margins and our ability to develop and deliver proposed products on a timely and competitive basis. Any delays in manufacturing and distribution will have an adverse impact on the price of our Company’s shares.
We may be subject to product liability claims.
The sale of the AO-Systems® in the future may expose us to the risk of significant losses resulting from product liability. Although we intend to obtain and maintain product liability insurance to offset some of this risk, we may be unable to secure such insurance or it may not cover certain potential claims against us.
We may not be able to afford to obtain insurance due to rising costs in insurance premiums in recent years. If we are able to secure insurance coverage, we may be faced with a successful claim against us in excess of our product liability coverage that could result in a material adverse impact on our business. If insurance coverage is too expensive or is unavailable to us, we may be forced to self-insure against product-related claims. Without insurance coverage, a successful claim against us and any defense costs incurred in defending ourselves may have a material adverse impact on our operations.
As a result of our limited operating history, we may not be able to correctly estimate our future operating expenses, which could lead to cash shortfalls.
- 15 -
We have only a limited operating history from which to evaluate our business. We have not generated revenue to date. Accordingly, our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in an early stage of development. We may not be successful in addressing such risks, and the failure to do so could have a material adverse effect on our business, operating results and financial condition.
Because of this limited operating history and because of the emerging nature of the markets in which we compete, our historical financial data is of limited value in estimating future operating expenses. Our budgeted expense levels are based in part on our expectations concerning future revenues. However, our ability to generate revenues depends largely on purchase orders generated from hospitals, hotels, retirement homes, government buildings, and cooling tower installations.
Moreover, if we generate orders from hospitals, hotels, retirement homes, government buildings, and cooling tower installations, the size of any future revenues depends on the choices and demand of individual consumers, which are difficult to forecast accurately. We may be unable to adjust our operations in a timely manner to compensate for any unexpected shortfall in revenues. Accordingly, a significant shortfall in demand for our products could have an immediate and material adverse effect on our business, results of operations, and financial condition.
Our operating results may fluctuate as a result of a number of factors, many of which are outside of our control. For these reasons, comparing our operating results on a period-to-period basis may not be meaningful, and you should not rely on our past results as any indication of our future performance. Our quarterly and annual expenses are likely to increase substantially over the next several years, and revenues from the sale of the AO-Systems® may not meet our expectations. Our operating results in future quarters may fall below expectations. Any of these events could adversely impact our business prospects and make it more difficult to raise additional equity capital at an acceptable price per share. Each of the risk factors listed in this “Risk Factors” section may affect our operating results.
Our business, the technology and the water treatment industry are constantly changing and evolving over time. Furthermore, we compete in an unpredictable industry and regulatory environment. Our ability to succeed depends on our ability to receive approval from the Environmental Protection Agency and being able to successfully compete in the water treatment market. As such, our actual operating results may differ substantially from our projections.
Hydrodynex has never earned a profit and is currently operating under a net loss. There is no guarantee that we will ever earn a profit.
From our inception on May 12, 2006 to the accounting period ended on May 31, 2014, we have not generated any revenue. Rather, we operate under a net loss, and has an accumulated deficit of $353,971 as of the period ended May 31, 2014. Hydrodynex does not currently have any revenue producing operations. We are not currently operating profitably, and it should be anticipated that we will operate at a loss at least until such time when the production stage is achieved, if production is, in fact, ever achieved.
If we are unable to obtain financing in the amounts and on terms and dates acceptable to us, we may not be able to expand or continue our operations and development and so may be forced to scale back or cease operations or discontinue our business. You could lose your entire investment.
We will need to obtain additional financing in order to complete our business plan. We currently do not have any operations and we have no income. We are an early stage company and we have not realized any revenues to date. We do not have sufficient capital to enable us to commence, implement and complete our business plan and based on our current operating plan, we do not expect to generate revenue that is sufficient to cover our expenses for at least the next twelve months. We will require financing in order to get regulatory approval and initiate operations described in the section entitled, "Business of the Issuer.” We need to raise a minimum of $400,000 to implement and complete the first phase of our business plan. There will be an addition requirement of $2,000,000 to complete the second phase of our business plan. There is no assurance that we will be successful in raising these funds and in the event were are successful, there is no assurance that the terms and conditions of these funds will be in the best interest of our company or our shareholders. We do not have any arrangements for financing and we may not be able to find such financing if required. We will need to obtain additional financing to operate our business for the next twelve months, and if we do not, our business will fail. We will raise the capital necessary to fund our business through a Prospectus and private offering of our common stock or units consisting of common stock and stock purchase warrants. Obtaining additional financing would be subject to a number of factors, including investor acceptance of Company’s business strategy, its technology and investor sentiment. These factors may adversely affect the timing, amount, terms, or conditions of any financing that we may obtain or make any additional financing unavailable to us.
- 16 -
We do not currently have any arrangements for financing and we can provide no assurance to investors we will be able to find such financing when such funding is required. Obtaining additional financing would be subject to a number of factors, including investor acceptance of our product and our business model. Furthermore, there is no assurance that we will not incur further debt in the future, that we will have sufficient funds to repay our future indebtedness, or that we will not default on our future debts, thereby jeopardizing our business viability. Finally, we may not be able to borrow or raise additional capital in the future to meet our needs or to otherwise provide the capital necessary to maintain our operations.
Our company anticipates that the funds that were raised from private placements by way of subscription agreements and funds advanced from directors will not be sufficient to satisfy our cash requirements for the next twelve month period. Also, there is no assurance that actual cash requirements will not exceed our estimates. In particular, additional capital may be required in the event that:
1.
we incur unexpected costs in our independent testing programs;
2.
we are unable to create a substantial market for our products;
3.
we incur any significant unanticipated expenses; and
4.
we find that we need to spend additional funds to educated the market and promote the new technology.
The occurrence of any of the aforementioned events could prevent us from pursuing our business plan, expanding our business operations and ultimately achieving a profitable level of operations.
We depend almost exclusively on outside capital to pay for the continued development of our business and the marketing of our products. Such outside capital may include the sale of additional stock, shareholder and director advances and/or commercial borrowing. There can be no assurance that capital will continue to be available if necessary to meet these continuing development costs or, if the capital is available, that it will be on terms acceptable to us. The issuance of additional equity securities by us will result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.
If we are unable to obtain financing in the amounts and on terms deemed acceptable to us, we may not be able to expand or continue sales of the AO-Systems® for the treatment of water and so may be forced to scale back or cease operations or discontinue business and you could lose your entire investment
Our company was recently formed, and we have not proven that we can generate a profit. If we fail to generate income and achieve profitability investment in our securities may be worthless.
We have no operating history and have not proved we can operate successfully. We face all of the risks inherent in a new business. If we fail, investments in our common stock will become worthless. From inception of May 12, 2006 to the audited period ended on May 31, 2014, we incurred a net loss of $353,971, and did not earn any revenue. Hydrodynex does not currently have any revenue producing operations.
We rely on our senior management and will be harmed if any or all of them leave.
Our success is dependent on the efforts, experience and relationships of Jerod Edington. If this individual were unable to continue in his role, the business would be adversely affected as to its business prospects and earnings potential. We do not currently carry any insurance to compensate for any such loss. Mr. Edington’s decisions and choices may not take into account standard engineering or managerial approaches marketing companies in the water treatment industry commonly use. Consequently, our operations, earnings, and ultimate financial success could suffer irreparable harm due to management's lack of experience in this industry.
We may find it very difficult or impossible for Hydrodynex to find suitable employees in the future or to find third party consultants to assist Hydrodynex.
Hydrodynex currently relies heavily upon the services and expertise of Jerod Edington. In order to implement the business plan of Hydrodynex, management recognizes that additional management will be required at some point in the future. However, on a near term basis, Hydrodynex will outsource most services and utilize independent consultants as much as possible. The director, which includes these one officer, is the only personnel currently. The officer can manage the office functions until Hydrodynex can generate enough revenues to hire employees.
Because a small number of existing shareholders own a large percentage of our voting stock, you will have minimal influence over shareholder decisions.
- 17 -
Certain individuals have significant stock ownership in our company and will retain significant control of Hydrodynex in the future. We anticipate that our founders, executive officers, directors, employees and early-stage investors will together own 100% of the voting power of our outstanding capital stock. As a result of such ownership concentration, this group will have significant influence over the management and affairs of our business. They will also exert considerable, ongoing influence over matters subject to stockholder approval, including the election of directors and significant corporate transactions, such as a merger, sale of assets or other business combination or sale of our business. This concentration of ownership may have the effect of delaying, deferring, or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other shareholders.
There are many competitors in our market and we may not be able to effectively compete against them.
The business of marketing water disinfection systems is highly competitive. This market segment includes numerous technologies, manufacturers, distributors, marketers and retailers that actively compete for the business of commercial water treatment in North America. In addition, the market is highly sensitive to the introduction of new products and technologies that may rapidly capture a significant share of the market. As a result, our ability to remain competitive depends in part upon its successful introduction and end user acceptance of a new product.
We are a development stage company, which means our operations may not be successful.
We were incorporated on May 12, 2006 and we have not executed our business model. Our ability to maintain and achieve profitability is dependent on the execution of our business plan to generate cash flow to fund future growth. There can be no assurance that our results of operations or marketing strategy will prove successful.
RISKS RELATED TO OUR FINANCIAL CONDITION AND BUSINESS MODEL
If we are unable to obtain additional capital, we may have to curtail or cease operations.
We expect that we will need to raise funds in October 2014 in order to meet our working capital requirements. At present, we don't have the funds to continue operations past October 2014 based upon our present monthly use of funds. We may not be able to obtain additional financing on terms favorable to us, if at all. If adequate funds are not available to us, we may have to curtail or cease operations after October 2014, which would materially harm our business and financial results. To the extent we raise additional funds through further issuances of equity or convertible debt or equity securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Furthermore, any debt financing secured by us in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities.
We do not have the funds needed to continue operations past October 2014.
We need to raise a minimum of $400,000 to implement and complete the first phase of our business plan, as well as to renegotiate the terms of our license agreement, if possible, to allow us to continue our business plan. Securing these funds or any funds to continue operations will be difficult and there is no guarantee that we can continue operations beyond October 2014.
We have no operating history that makes an evaluation of our business difficult.
Our lack of operating history makes it difficult to evaluate our current business and prospects or to accurately predict our future revenues or results of operations. Our business model, and accordingly our revenue and income potential, is new and unproven. In addition, early-stage companies are subject to risks and difficulties frequently encountered in new and rapidly evolving markets.
We have a new and unproven business model, a new technology and may not generate sufficient revenues for our business to survive or be successful.
Our business model is based on the commercial viability of a new patented technology and products not sold previously in North America. In order for our business to be successful, we must not only develop viable marketing channels that directly generate revenues, but also provide educational content to end users to create demand for our products and
- 18 -
technology. Our business model assumes that end users in many markets will see the value of our technology and products and we will be able to generate revenues through sales to end users. Each of these assumptions is unproven, and if any of the assumptions are incorrect, we may be unable to generate sufficient revenues to sustain our business or to obtain profitability. At the present time, we have no contracts, arrangements, or agreements with either end users or distributors.
Because of our limited resources and the speculative nature of our business, there is substantial doubt as to our ability to operate as a going concern.
The report of our independent auditors, on our audited financial statements as of and for the year ended May 31, 2014 indicates that there are a number of factors that raise substantial doubt about our ability to continue as a going concern. Our operations are dependent upon our ability to obtain financing and our ability to achieve future profitable operations from the development of our business model. If we are not able to continue as a going concern, it is likely Hydrodynex will cease operations.
We have no operating history and expect to incur losses in the future.
We have no operating history and have generated no revenues. We have not achieved profitability and expect to incur losses for the foreseeable future. We expect those losses to increase as we continue to incur expenses to develop our products and services. We believe that our business depends on our ability to significantly increase revenues and to limit our operating expenses. If our revenues fail to grow at anticipated rates or our operating expenses increase without a commensurate increase in our revenues, or we fail to adjust operating expense levels appropriately, we may never be able to achieve profitability.
Our future operating results are likely to be volatile and may cause our equity value to fluctuate.
Our future revenues and operating results, if any, are likely to vary from quarter to quarter due to a number of factors, many of which are outside of our control. Factors, which may cause our revenues and operating results to fluctuate, include the following:
•
the willingness of distributors to market our products;
•
market acceptance of our technology and AO Systems;
•
the timing and uncertainty of sales cycles;
•
new products and services offered by current or future competitors; and
•
general economic conditions, as well as economic conditions specific to the water treatment industry.
We are subject to all of the risks and uncertainties associated with the water treatment industry, all of which may have an adverse impact on our business and results of operations.
Our future operating results will depend upon numerous factors beyond our control, including the acceptability of our products and technology by end users, national, regional and local economic conditions, changes in demographics, the availability of alternative forms of water treatment, critical reviews and existing competition, which change rapidly and cannot be predicted. If we are unable to successfully anticipate and respond to changes in attitude by end users, our business and operating results will be adversely affected.
Current or future government regulations may add to our operating costs.
We may face unanticipated operating costs because of potential changes in governmental regulations related to water treatment standards. We have no assurance that the independent testing to be undertaken by NSF International will result in favorable data that will be accepted by the Environmental Protection Agency. Laws and regulations may be introduced and court decisions reached that affect the water treatment standards or other characteristics of water deemed to be disinfected. Complying with new regulations could increase our operating costs. Furthermore, we may be subject to the laws of various jurisdictions where we actually conduct business. Our failure to qualify to do business in a jurisdiction that requires us to do so could subject us to fines or penalties and could have a material adverse impact on our business and operations.
If we fail to attract end users, distributors or professional sales personnel for our products may have an adverse impact on our business.
Our success will depend upon our ability to attract capable distributors and as well as in-house sales representatives to enter into arrangements with us to sell our products to end users. If we do not continually augment and improve our
- 19 -
marketing channels, we will not be able to sustain a sales level that will support our operations without the infusion of additional capital.
If we do not effectively educate end users on the benefits of the AO-Systems®, we will not have sufficient demand for our products.
Our business plan is predicated on our company attracting active and loyal support from end users interested in the disinfection of water, principally hospitals. Our target market will be end users that have a specific need in having the safest, purest and healthiest water possible for consumption or utilization in their commercial business. There can be no assurance that there will be significant support from our efforts to educate end users on this new technology of disinfection of water. Failure to achieve recognition and acceptance of this new technology by hospital and other commercial end-users in a timely fashion will have a material adverse effect on the sales cycle and may require us to incur unexpected incremental marketing expenses to educate and inform the market place.
Delivery of our products may be interrupted due to international political situations, natural disasters or other causes.
Our products are manufactured in Europe and delivery can be a problem. We are subject to the risk that delivery of our products may be interrupted as a result of natural disasters such as earthquakes and fires or capacity constraints with our vendors’ or suppliers’ hardware. Any such interruptions may lead to a loss of customers or distributors and, accordingly, may adversely affect our business and results of operations.
RISKS RELATED TO OUR STOCK
There is not now, and there may not ever be, an active market for our common stock.
There currently is no market for our common stock. Further, although the common stock of Hydrodynex is quoted on the OTC Bulletin Board, trading of its common stock may be extremely sporadic. For example, several days may pass before any shares are traded. There can be no assurance that although listed on an exchange, a more active market for such common stock would develop. Accordingly, investors must therefore bear the economic risk of an investment in our shares for an indefinite period of time.
If you purchase shares of our common stock you will experience immediate and substantial dilution.
If you purchase shares, you will incur immediate and substantial dilution in pro forma net tangible book value. If Hydrodynex sells additional shares of common stock or issues warrants in the future and these holders of outstanding options and warrants exercise those options and warrants, you will incur further dilution. In the event we obtain any additional funding, such financings are likely to have a dilutive effect on the holders of our securities. In addition, we have adopted an employee stock option plan under which officers, directors, consultants and employees will be eligible to receive stock options exercisable for our securities at exercise prices that may be lower than the Offering Price. Such stock option grants, if any, may dilute the value of the securities.
If our stock trades at a relatively small volume, shareholders may not be able to sell their shares without depressing the market price of the shares.
If a market for our common stock is established, it may be possible that a relatively small volume of shares will trade on a daily basis. A small volume is indicative of an illiquid market. In the event there is a relatively small volume of shares being traded on a daily basis, shareholders may be unable to sell their shares without causing a depressive effect on the price of our common stock.
Our stock is a penny stock. Trading of our stock may be restricted by the SEC's penny stock regulations and the NASD’s sales practice requirements, which may limit a stockholder's ability to buy and sell our stock.
Hydrodynex’ common shares may be deemed to be “penny stock” as that term is defined in Regulation Section “240.3a51-1” of the Securities and Exchange Commission (the “SEC”). Penny stocks are stocks: (a) with a price of less than U.S. $5.00 per share; (b) that are not traded on a “recognized” national exchange; (c) whose prices are not quoted on the NASDAQ automated quotation system (NASDAQ - where listed stocks must still meet requirement (a) above); or (d) in issuers with net tangible assets of less than U.S. $2,000,000 (if the issuer has been in continuous operation for at least three years) or U.S. $5,000,000 (if in continuous operation for less than three years), or with average revenues of less than U.S. $6,000,000 for the last three years.
- 20 -
Section “15(g)” of the United States Securities Exchange Act of 1934, as amended, and Regulation Section “240.15g(c)2” of the SEC require broker dealers dealing in penny stocks to provide potential investors with a document disclosing the risks of penny stocks and to obtain a manually signed and dated written receipt of the document before effecting any transaction in a penny stock for the investor’s account. Potential investors in Hydrodynex’ common shares are urged to obtain and read such disclosure carefully before purchasing any common shares that are deemed to be “penny stock”.
Moreover, Regulation Section “240.15g-9” of the SEC requires broker dealers in penny stocks to approve the account of any investor for transactions in such stocks before selling any penny stock to that investor. This procedure requires the broker dealer to: (a) obtain from the investor information concerning his or her financial situation, investment experience and investment objectives; (b) reasonably determine, based on that information, that transactions in penny stocks are suitable for the investor and that the investor has sufficient knowledge and experience as to be reasonably capable of evaluating the risks of penny stock transactions; (c) provide the investor with a written statement setting forth the basis on which the broker dealer made the determination in (ii) above; and (d) receive a signed and dated copy of such statement from the investor confirming that it accurately reflects the investor’s financial situation, investment experience and investment objectives. Compliance with these requirements may make it more difficult for investors in Hydrodynex’ common shares to resell their common shares to third parties or to otherwise dispose of them. Stockholders should be aware that, according to Securities and Exchange Commission Release No. 34-29093, dated April 17, 1991, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include:
(i)
control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer
(ii)
manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases
(iii)
boiler room practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons
(iv)
excessive and undisclosed bid-ask differential and markups by selling broker-dealers
(v)
the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses
Our management is aware of the abuses that have occurred historically in the penny stock market. Although we do not expect to be in a position to dictate the behavior of the market or of broker-dealers who participate in the market, management will strive within the confines of practical limitations to prevent the described patterns from being established with respect to our securities.
RISKS RELATED TO OUR INTELLECTUAL PROPERTY
Our intellectual property rights are valuable and our inability to protect them or keep them could reduce the value of our products, services and brand.
We do not own any patents or intellectual property. We have an exclusive license agreement with Hydrosystemtechnik GmbH, which initially grants us the right to market the AO-Systems® in North America and in the future, but this license can be reverted to non-exclusive or cancelled by the licensor at any time. The patents issued in the U.S. were granted in 1995. U.S. trademarks, trade secrets, copyrights and other intellectual property rights are owned by the licensor, which we have access to by virtue of the terms and conditions of the exclusive License Agreement. This intellectual Property is currently outside of our direct control and could jeopardize our ability to implement our business plan. In addition, the efforts made by Hydrosystemtechnik, GmbH, to protect the intellectual property rights may not be sufficient or effective. Any significant impairment of the intellectual property rights could harm our business indirectly or our ability to compete. Protecting the intellectual property rights is costly and time consuming, and the unauthorized use of the intellectual property could cause these costs to rise significantly and materially affect our operating results. We are required to pay 50% of the direct costs related to preparing and prosecution of patents and patent applications, including legal fees, filing fees maintenance fees and transaction costs within the licensed territory, so long as our license agreement with Hydrosystemtechnik GmbH remains in effect.
While the goal of Hydrosystemtechnik GmbH is to obtain patent protection for their innovations, they may not be patentable or they may choose not to protect certain innovations that later turn out to be important for our business. Even if Hydrosystemtechnik GmbH does obtain protection for its innovations, the scope of protection gained may be insufficient or a
- 21 -
patent issued may be deemed invalid or unenforceable, as the issuance of a patent is not conclusive as to its validity or as to the enforceable scope of the claims of the patent. The patenting process, enforcement of issued patents, and defense against claims of infringement are inherently costly and risky. Hydrosystemtechnik GmbH may not have the financial resources to defend its patents, thereby reducing our competitive position and our business prospects. Specific risks associated with the patent process include the following:
The United States Patent and Trademark Office may not grant patents of meaningful scope based on the applications already filed and those that may be filed in the future.
If the current patents owned by our licensor do not adequately protect the technology and the industrial applications, then we will not be able to prevent imitation and the product may not be commercially viable.
Changes in or different interpretations of patent laws in the United States may permit others to use our discoveries or to develop and commercialize our technology and products without providing any compensation to us.
Although we try to avoid infringement, there is the risk that we will use a patented technology owned by another person or entity and/or be sued for infringement. For example, U.S. patent applications are confidential while pending in the Patent and Trademark Office, and patent offices in foreign countries often publish patent applications for the first time six months or more after filing. Further, we may not be aware of published or granted conflicting patent rights. Any conflicts resulting from patent applications and patents of others could significantly reduce the coverage of the patents and limit our ability to obtain meaningful patent protection. In addition, defending or indemnifying a third party against a claim of infringement can involve lengthy and costly legal actions, and there can be no guarantee of a successful outcome.
ITEM 2.
ITEM 2. Properties.
Our executive office is currently located at 451 W. 21st Ave., Spokane, WA 99203. The 150 square foot office is provided by Jerod Edington, officer and director of Hydrodynex, at no cost to Hydrodynex. We believe our current premises are adequate for our current operations and we do not anticipate that we will require any additional premises until such time as Hydrodynex raises additional capital.
ITEM 3.
ITEM 3. Legal Proceedings.
We are not involved in any legal proceedings, and there are no material pending legal proceedings of which we are aware.
ITEM 4.
ITEM 4. (Removed and Reserved)
- 22 -
PART II
ITEM 5.
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Our common stock has been listed on the OTC Bulletin Board since March 26, 2009 but has never had a price quoted. Since its listing on OTC Bulletin there has been no trading activity of any kind and consequently there are no historical share prices to report.
The transfer agent of Hydrodynex is Nevada Agency and Transfer Company, 50 West Liberty Street, Suite 880, Reno, Nevada 89501.
As of May 31, 2014, there were 48 holders of record of Hydrodynex’ common stock, of which 2,874,880 were issued and outstanding.
We have never paid cash dividends on our common stock. We presently intend to retain future earnings, if any, to finance the expansion of our business and we do not anticipate that any cash dividends will be paid in the foreseeable future. Our future dividend policy will depend on our earnings, capital requirements, expansion plans, financial condition and other relevant factors.
Recent Sales of Unregistered Securities; Use of Proceeds From Unregistered Securities
On August 30, 2013, we issued 545,000 unregistered shares of its common stock, par value $0.001, at $0.05 per share from our treasury to two creditors of Hydrodynex, Inc. in exchange for outstanding loans in aggregate of $27,250 and aggregate interest accrued of $0. These loan proceeds were used for regular business operations. A total of 405,000 shares were issued to affiliate Jerod Edington, Officer and Director of Hydrodynex, in exchange for the loans due to him. A total of 140,000 shares were issued to Marycliff Investment Corp., a related party entity owned by Jerod Edington's mother, Sherry Edington, in exchange for the loans due to it. In the issuance of the securities referenced under Item 1.01 of this report we are relying on the exemption from registration provided by Section 4(2) of the Securities Act of 1933 for sales to sophisticated investors given full disclosure. We believed that Section 4(2) was available because the offer and sale did not involve a public offering and there was not general solicitation or general advertising involved in the offer or sale and no fees were paid in connection with the transaction.
On January 31, 2014, the Company entered into a definitive agreement relating to the private placement of $3,000 of its securities through the sale of 30,000 shares of its common stock at $0.10 per share to an investor. Upon closing of the private placement, there were no fees, commissions, or professional fees for services rendered in connection with the private placement. The placement was arranged and undertaken by the officers of the Company. The private placement of these securities was exempt from registration under pursuant to Section 4(2) of the Securities Act of 1933, as amended. The company sold these restricted shares to further capitalize the Company in order to pay operating expenses and to execute its business plan.
ITEM 6.
ITEM 6. Selected Financial Data
Not applicable.
ITEM 7.
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
THE FOLLOWING PLAN OF OPERATIONS SECTION SHOULD BE READ IN CONJUNCTION WITH OUR FINANCIAL STATEMENTS AND THE NOTES THERETO INCLUDED IN THIS ANNUAL REPORT ON FORM 10-K. ALL STATEMENTS IN THIS ANNUAL REPORT RELATED TO HYDRODYNEX’ CHANGING FINANCIAL OPERATIONS AND EXPECTED FUTURE OPERATIONAL PLANS CONSTITUTE FORWARD-LOOKING STATEMENTS. THE ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE ANTICIPATED OR EXPRESSED IN SUCH STATEMENTS.
A. General.
Hydrodynex, Inc. was organized under the laws of the state of Nevada on May 12, 2006 to develop a business as a marketer of the AO-Systems® water treatment units. We intend to sell and distribute the AO-System® products in North America under the terms of our license agreement with Hydrosystemtechnik GmbH. Since commencement of operations in
- 23 -
2006, substantially all of our efforts to date have been devoted to and limited primarily to organization, initial capitalization, market research, producing marketing materials and a website, securing a marketing agreement, preparing a comprehensive business and operating plan, evaluating the regulatory requirements to sell water treatment systems in the U.S., Canada and Mexico, and undertaking a marketing feasibility study. Extensive research has been done on competing technologies and the water contaminants that most adversely affect water systems at the present time. Legionella protection is the strongest market opportunity identified by Hydrodynex to date. We plan to make Legionella our primary target market because of its wide prevalence and the high percentage of death resulting from infection.
Under our license agreement with our licensor Hydrosystemtechnik, we paid non-refundable license fees creditable to royalty payments in the aggregate amount of 30,000 in 2007 and 2009. A third license fee in the amount of 20,000 will be due upon certification and approval of the AO-Systems® by the US Environmental Protection Agency for commercial sales in the United States.
Due to the fact that we did not meet certain milestones and minimum annual sales targets under the license agreement with Hydrosystemtechnik, our right to manufacture the AO-System products has automatically expired and our licensor may change the agreement from an exclusive agreement to a non-exclusive agreement and may terminate the agreement at any time. In order to remedy this situation we need to raise at least $400,000 and re-negotiate the terms of the license agreement.
Our plan of operation for the next 12 months, if we are able to raise sufficient capital resources and re-negotiate our license agreement, will be the execution of our strategic business plan. Hydrodynex intends to operate in two phases as follows:
Phase 1: Finalization of the Strategic Marketing Plan, initial start-up capital realization through a second private stock offering, paying for the AO-System® test reactor unit, undertaking independent testing, securing EPA and State certification, and hiring/training sales and technical personnel.
Phase 2: Initiation of marketing and sales activities in selected markets in North America (U.S., Canada, and Mexico). Full scale commercialization of the AO-System®, including industrialization and after-sale service agreements, for the markets covered by Hydrodynex. As part of its effort to commercialize the AO-System®, Hydrodynex plans to offer mobile systems which may use a film pouch packaging system.
We need to raise a minimum of $400,000 to complete the first phase of our plan of operations and $2,000,000 to complete the second phase, for a total of $2,400,000 to implement both phases of our business plan.
Subject to raising additional capital, our projected monthly rate of expenditure is estimated at $3,000 for general and administrative costs. We anticipate that supporting our operations and implementing Phase I of our business plan for the next 12 months will require a minimum capital raising of $400,000. This includes approximately $30,000 for accounting, legal and auditing fees. The balance of the funds would be utilized for independent testing, purchase of equipment for testing, marketing materials, advertising, insurance, employee training, travel, office lease, licenses, shipping and import costs, employee salary, and other budgeted costs.
Hydrodynex is also considering other business sectors at this time and on June 18, 2014, the Company entered into a definitive Sixty (60) day Option to Purchase Assets Agreement to purchase all of the assets of Zoydan Games, Inc (“Zoydan”), a private company organized in the state of Washington on July 8, 2011. The agreement calls for this issuance of Forty Two Million (42,000,000) shares of restricted common stock to be issued to Zoydan Games, Inc. (“Zoydan”), which will be exchanged for specific assets of Zoydan and subsequently disbursed to the existing shareholders of Zoydan. Zoydan Games, Inc. was organized as a card and board game design, development, publishing and specialty marketing company. The acquisition of the assets of Zoydan will be subject to a vote of the shareholders of the Company pursuant to a future special meeting of the shareholders. On July 24, 2014, the Company and Zoydan agreed to extend the option date to September 15, 2014 and the option has not been exercised.
Hydrodynex’ Exclusive Technology License Agreement
We entered into a Marketing, Distribution and License Agreement with Hydrosystemtechnik GmbH September 3, 2007. On August 30, 2008, we entered into an Amended Marketing, Distribution and License Agreement, or amended license agreement, with Hydrosystemtechnik, which has the same effective date as the original license agreement, September 3, 2007, and supersedes the original license agreement. Under the amended license agreement, we were granted the right to sell water disinfection systems based on the AO-System® technology in all markets (except the dental market) in Canada, the United States, and Mexico on an exclusive basis for a period of three years after the effective date of the license agreement. The
- 24 -
license was to remain exclusive subject to Hydrodynex achieving certain milestones. The main milestones were (a) leasing or purchasing an AO-System® prior to November 30, 2009, as extended by the licensor, and (b) obtaining, by March 3, 2010, verification and certification of the AO-System® technology by the U.S. EPA necessary for commercialization and selling water disinfection systems in whole or in part within the United States, (c) make application to six states in the Western U.S. for certification of the AO-System® technology within 90 days after receiving the NSF and EPA verification, (d) sell, deliver and install at least one AO-System® in the U.S. in the two year exclusivity period following technology verification, and (e) we are required to demonstrate financial responsibility in the form of a bank credit line or equity funding of not less than $500,000 The milestones were not satisfied, but the licensor has not as of this time notified us that the exclusive license has been reduced to a non-exclusive status.
We were also required, beginning in the year beginning September 3, 2009, to meet certain minimum annual sales targets, based on net purchase value, for sales of AO-System® products in the North American territory, which increase from 30,000 in year three to 500,000 in year six and thereafter, in order to maintain the exclusivity of the license. We have failed to meet the minimum annual sales targets at in each year and the licensor, Hydrosystemtechnik GmbH, has the option to revert the license agreement to a non-exclusive marketing agreement and under the terms of the license agreement our right to manufacture has automatically expired.
We have paid a non-refundable license fees in the aggregate amount of 30,000 and a third license fee in the amount of 20,000 will be due upon certification and approval of the AO-Systems® by the US Environmental Protection Agency for commercial sales in the United States which is indicated as a license fee payable of $25,157 in our balance sheet. We are obligated to pay a royalty on the products actually assembled or manufactured and sold to third parties in the amount of 10% of the net selling price on all AO-Systems®. We are not obligated to pay a royalty on finished AO-Systems® purchased from Hydrosystemtechnik and resold. We are obligated to pay fifty percent of the direct costs related to preparing and prosecution of patents and patent applications in the U.S., Canada or Mexico, including legal fees, filing fees, maintenance fees, and transaction costs, so long as the license agreement remains in effect. We have paid $6,997 for patent fees thus far and expensed the entire balance of $6,997 of the prepaid patent application costs on June 30, 2011 since we are currently unable to finance the patent application process and secure EPA approval of the AO-System in order to begin selling in the United States within the time period specified in the agreement.
We plan to re-negotiate the license agreement with Hydrosystemtechnik to get the exclusive rights extended, but that is a forward looking statement and is not likely to be successful unless certain funding can be brought into Hydrodynex and reasonable terms can be reached with the licensor.
The license agreement terminates after ten years, in September 2017, with an option by us to extend the license for an additional ten years on an exclusive basis, as long as the required minimum annual sales volume is maintained. The licensor, Hydrosystemtechnik GmbH, has the right to terminate the license agreement, after a notice and cure period, if we are in default of any obligation in the agreement, The sales volume requirements were not been reached for the three consecutive years and the agreement can be terminated by the licensor at any time.
If we can raise sufficient funds and re-negotiate the license agreement, we plan to undertake to secure technology verification from NSF, an independent third party testing laboratory, accredited by the EPA, to legally sell AO-Systems® in the United States, but we have not initiated this process because we have yet to pay the remaining balance of 17,625 for the AO-System® test reactor unit owed to our licensor Hydrosystemtechnik. When we have sufficient funds to pay the remaining balance due on the test unit, arrangements for payment and shipping to the U.S. of the test reactor unit will be made.
Product Research and Development Plans
We do not plan to engage in any research and development at this time. The AO-System® product has been developed by our licensor, Hydrosystemtechnik, GmbH and is ready for sale to the consumer.
Results of Operations
Since Hydrodynex was formed on May 12, 2006, it has not earned any revenues and has incurred a net loss since its inception of $353,971 through May 31, 2014. The following table provides selected financial data about our company for the years ended May 31, 2014 and May 31, 2013, respectively.
- 25 -
For the year ended May 31, 2014, our total operating expenses were $9,137 as compared to $14,659 for the eleven months ended May 31, 2013. Our operating expenses have decreased between these time periods by $5,522 and until the company receives additional financing, we do not presently expect our expenses to increase in next twelve months. The total operating expenses were lower in the most recent year ended due mainly to a decrease in professional fees and general and administrative costs. The year ended May 31, 2014 included the following major expenses:
1. Professional fees including legal and Accounting - $8.282
2. General and Administrative Fees - $855
Our cash in the bank at May 31, 2014 was $162. Net cash used in operating activities during the year ended May 31, 2014 was $10,914, compared to net cash used in operating activities during the eleven months ended May 31, 2013 of $9,354, a difference of $1,560.
Net cash provided by financing activities since inception through May 31, 2014 was $304,425 from the sale of our common stock and warrants, advances from officers, proceeds from convertible notes payable, and accrued expenses from a related party. Net cash provided by financing activities for the year ended May 31, 2014 was $9,000 from related party advances compared to $10,200 for the eleven months ended May 31, 2013, a difference of $1,200.
In their report on our May 31, 2014 audited financial statements, our auditors express an opinion that there is substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. We have had no revenues since inception. Our continuation as a going concern is dependent upon future events, including our ability to raise additional capital and to generate positive cash flows. There can be no assurances to that effect.
Liquidity and Capital Resources
Since inception, we have financed our operations from private placements of equity securities and loans from shareholders. We do not have any available lines of credit. As of May 31, 2014, we had cash in the amount of $162. Net cash provided by financing activities was $9,000 during the year ended May 31, 2014. We raised only $6,000 in capital during the year ended May 31, 2014 from financing activities with related parties in the form of unsecured and non-interest bearing loans and loans converted to shares. $3,000 was raised from the sale of common stock to a non-related party. We will need to raise additional capital, take loans, or generate revenue in October 2014 or curtail or cease our basic operations. We need to raise a minimum of $400,000 to implement and complete the first phase of our business plan, as well as to renegotiate the terms of our license agreement, if possible, to allow us to continue our business plan.
On September 30, 2011, we converted $8,385 in account payables owed to a services provider and $37,600 in accrued consulting fees owed to an officer and director of the company into 919,700 three-year warrants, where one warrant entitles to purchase one share of our restricted common stock at an exercise price of $0.01 per share.
On September 30, 2011, we converted $16,300 in advances from officer and director Jerod Edington into restricted common shares at $0.05 per share. A total of 326,000 shares were issued in this transaction.
On August 30, 2013, we issued 545,000 unregistered shares of its common stock, par value $0.001, at $0.05 per share from our treasury to two creditors of Hydrodynex, Inc. in exchange for outstanding loans in aggregate of $27,250 and aggregate interest accrued of $0. A total of 405,000 shares were issued to affiliate Jerod Edington, officer and director of Hydrodynex, in exchange for the $20,250 in loans due to him. A total of 140,000 shares were issued to Marycliff Investment
- 26 -
Corp., a related party entity owned by Jerod Edington's mother, Sherry Edington, in exchange for the $7,000 loans due to it. In the issuance of the securities referenced under Item 1.01 of this report we are relying on the exemption from registration provided by Section 4(2) of the Securities Act of 1933 for sales to sophisticated investors given full disclosure. We believed that Section 4(2) was available because the offer and sale did not involve a public offering and there was not general solicitation or general advertising involved in the offer or sale and no fees were paid in connection with the transaction.
Officer and director Jerod Edington advanced $6,000 to our company for working capital purposes during the year ended May 31, 2014. As of May 31, 2014, the total amount of advances due to our officer and director was $6,000, which were unsecured and non-interest bearing, and maturing on as follows:
-$1,000 on September 20, 2014
-$2,000 on October 23, 2014
-$3,000 on April 19, 2015
As of May 31, 2014, the total amount of advances due to non-affiliate related parties was $0.
On January 31, 2014, the Company entered into a definitive agreement relating to the private placement of $3,000 of its securities through the sale of 30,000 shares of its common stock at $0.10 per share to an investor. Upon closing of the private placement, there were no fees, commissions, or professional fees for services rendered in connection with the private placement. The placement was arranged and undertaken by the officers of the Company. The private placement of these securities was exempt from registration under pursuant to Section 4(2) of the Securities Act of 1933, as amended. The company sold these restricted shares to further capitalize the Company in order to pay operating expenses and to execute its business plan.
We do not have sufficient capital resources to carry on operations past October 2014. We cannot assure you that we will generate sufficient additional capital or revenues, if any, to fund our operations beyond October 2014, but we plan to raise additional capital in a private stock offering to secure funds needed to finance our plan of operation for at least the next twelve months, or enter into loans from existing shareholders to support operations. We are pursuing potential equity financing, sub-licensing and other collaborative arrangements that may generate additional capital for us. However, these are forward-looking statements, and there may be changes that could consume available resources before such time. Our long term capital requirements and the adequacy of our available funds will depend on many factors, including the reporting company costs, public relations fees, technology verification costs, among others.
If we cannot generate sufficient financing or revenues to continue operations, we will have to suspend or cease operations. By virtue of our inability to secure financing or generate revenues over the preceding year, we will begin to seek out other sources of cash, including new investors, joint venture and strategic partners or loans from our officers or directors. If we cease operations, we do not know what we would do subsequently and we have no plans to do anything in such event. We have no plans to dissolve statutorily at this time, under any circumstances. We are engaged in general discussions with multiple companies who may be interested in acquiring us. As of this date there is no definitive agreement signed and there is no assure that any acquisition will be feasible in the future and in the event there is an acquisition, there is no assurance that it will be in the best interest of our shareholders.
Critical Accounting Policies and Estimates
This discussion and analysis of our financial condition and results of operations are based on our financial statements that have been prepared under accounting principles generally accepted in the United States of America. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. All significant accounting policies have been disclosed in Note 2 to the financial statements included in this Form 10-K.
Subsequent Events
On June 18, 2014, the Company entered into a definitive Sixty (60) day Option to Purchase Assets Agreement to purchase all of the assets of Zoydan Games, Inc (“Zoydan”), a private company organized in the state of Washington on July 8, 2011. The agreement calls for this issuance of Forty Two Million (42,000,000) shares of restricted common stock to be issued to Zoydan Games, Inc. (“Zoydan”), which will be exchanged for specific assets of Zoydan and subsequently disbursed to the existing shareholders of Zoydan. Zoydan Games, Inc. was organized as a card and board game design, development,
- 27 -
publishing and specialty marketing company. The acquisition of the assets of Zoydan will be subject to a vote of the shareholders of the Company pursuant to a special meeting of the shareholders estimated to be held on or about August 1, 2014.
On July 24, 2014, the Company and Zoydan agreed to extend the option date to September 15, 2014.
On August 8, 2014, the Chief Executive Officer of the Company advanced the Company $500 for a term of one year at 0% interest.
ITEM 7A.
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
ITEM 8.
ITEM 8. Financial Statements and Supplementary Data
- 28 -
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Hydrodynex, Inc.
Spokane, WA
We have audited the accompanying balance sheets of Hydrodynex, Inc. (the “Company”), as of May 31, 2014 and 2013 and the related statements of operations, stockholder’s equity (deficit) and cash flows for the 12 months ended May 31, 2014 and for the 11 months ended May 31, 2013. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of May 31, 2014 and 2013 and the results of its operations and its cash flows for the 12 months ended May 31, 2014 and for the 11 months ended May 31, 2013 in conformity with accounting principles generally accepted in the United States of America.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company had an accumulated deficit at May 31, 2014 and had a net loss and cash used in operating activities for the 12 months then ended. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regards to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/Li and Company, PC
Li and Company, PC
Skillman, New Jersey
September 15, 2014
- 29 -
- 30 -
- 31 -
- 32 -
- 33 -
Hydrodynex, Inc.
May 31, 2014 and 2013
Notes to the Financial Statements
Note 1 - Organization and Operations
Hydrodynex, Inc. (a development stage company) (“Hydrodynex” or the “Company”) was incorporated on May 12, 2006 under the laws of the State of Nevada for the purpose of the marketing and distribution of AO-System (Anodic Oxidation) water treatment units under an exclusive license agreement for the Territory of North America comprising the United States, Canada and Mexico.
Note 2 - Significant and Critical Accounting Policies and Practices
The Management of the Company is responsible for the selection and use of appropriate accounting policies and the appropriateness of accounting policies and their application. Critical accounting policies and practices are those that are both most important to the portrayal of the Company’s financial condition and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. The Company’s significant and critical accounting policies and practices are disclosed below as required by generally accepted accounting principles.
Basis of Presentation
The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Fiscal Year
The Company elected June 30 as its fiscal year ending date upon formation.
On December 21, 2012, a board resolution authorized the change of the Company’s fiscal year end date from June 30 to May 31.
Use of Estimates and Assumptions and Critical Accounting Estimates and Assumptions
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date(s) of the financial statements and the reported amounts of revenues and expenses during the reporting period(s).
Critical accounting estimates are estimates for which (a) the nature of the estimate is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change and (b) the impact of the estimate on financial condition or operating performance is material. The Company’s critical accounting estimates and assumptions affecting the financial statements were:
(i)
Assumption as a going concern: Management assumes that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business;
(ii)
Valuation allowance for deferred tax assets: Management assumes that the realization of the Company’s net deferred tax assets resulting from its net operating loss (“NOL”) carry-forwards for Federal income tax purposes that may be offset against future taxable income was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are offset by a full valuation allowance. Management made this assumption based on (a) the Company has incurred recurring losses, (b) general economic conditions, and (c) its ability to raise additional funds to support its daily operations by way of a public or private offering, among other factors.
These significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.
- 34 -
Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly.
Actual results could differ from those estimates.
Fair Value of Financial Instruments
The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and has adopted paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:
Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.
The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable, and license fee payable, approximate their fair values because of the short maturity of these instruments.
Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated.
Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Related Parties
The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.
Pursuant to Section 850-10-20 the related parties include a. affiliates of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees,
- 35 -
such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.
Commitments and Contingencies
The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.
The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
Foreign Currency Transactions
The Company applies the guidelines as set out in Section 830-20-35 of the FASB Accounting Standards Codification (Section 830-20-35) for foreign currency transactions. Pursuant to Section 830-20-35 of the FASB Accounting Standards Codification, foreign currency transactions are transactions denominated in a currency other than U.S. Dollar, the Company’s functional currency. Foreign currency transactions may produce receivables or payables that are fixed in terms of the amount of foreign currency that will be received or paid. A change in exchange rates between the functional currency and the currency in which a transaction is denominated increases or decreases the expected amount of functional currency cash flows upon settlement of the transaction. That increase or decrease in expected functional currency cash flows is a foreign currency transaction gain or loss that generally shall be included in determining net income for the period in which the exchange rate changes. Likewise, a transaction gain or loss (measured from the transaction date or the most recent intervening balance sheet date, whichever is later) realized upon settlement of a foreign currency transaction generally shall be included in determining net income for the period in which the transaction is settled. The exceptions to this requirement for inclusion in net income of transaction gains
- 36 -
and losses pertain to certain intercompany transactions and to transactions that are designated as, and effective as, economic hedges of net investments and foreign currency commitments. Pursuant to Section 830-20-25 of the FASB Accounting Standards Codification, the following shall apply to all foreign currency transactions of an enterprise and its investees: (a) At the date the transaction is recognized, each asset, liability, revenue, expense, gain, or loss arising from the transaction shall be measured and recorded in the functional currency of the recording entity by use of the exchange rate in effect at that date as defined in section 830-10-20 of the FASB Accounting Standards Codification; and (b) At each balance sheet date, recorded balances that are denominated in a currency other than the functional currency of the recording entity shall be adjusted to reflect the current exchange rate.
Stock-Based Compensation for Obtaining Employee Services
The Company accounts for its stock based compensation in which the Company obtains employee services in share-based payment transactions under the recognition and measurement principles of the fair value recognition provisions of section 718-10-30 of the FASB Accounting Standards Codification. Pursuant to paragraph 718-10-30-6 of the FASB Accounting Standards Codification, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows:
·
Expected term of share options and similar instruments: The expected life of options and similar instruments represents the period of time the option and/or warrant are expected to be outstanding. Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments. Pursuant to paragraph 718-10-S99-1, it may be appropriate to use the simplified method, i.e., expected term = ((vesting term + original contractual term) / 2), if (i) A company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) A company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) A company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as the company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.
·
Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
·
Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments.
·
Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.
- 37 -
The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award.
Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services
The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”).
Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows:
·
Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2 of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.
·
Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
·
Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments.
·
Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments.
Pursuant to ASC paragraph 505-50-25-7, if fully vested, non-forfeitable equity instruments are issued at the date the grantor and grantee enter into an agreement for goods or services (no specific performance is required by the grantee to retain those equity instruments), then, because of the elimination of any obligation on the part of the counterparty to earn the equity instruments, a measurement date has been reached. A grantor shall recognize the equity instruments when they are issued (in most cases, when the agreement is entered into). Whether the corresponding cost is an immediate expense or a prepaid asset (or whether the debit should be characterized as contra-equity under the requirements of paragraph 505-50-45-1) depends on the specific facts and circumstances. Pursuant to ASC paragraph 505-50-45-1, a grantor may conclude that an asset (other than a note or a receivable) has been received in return for fully vested, non-forfeitable equity instruments that are issued at the date
- 38 -
the grantor and grantee enter into an agreement for goods or services (and no specific performance is required by the grantee in order to retain those equity instruments). Such an asset shall not be displayed as contra-equity by the grantor of the equity instruments. The transferability (or lack thereof) of the equity instruments shall not affect the balance sheet display of the asset. This guidance is limited to transactions in which equity instruments are transferred to other than employees in exchange for goods or services. Section 505-50-30 provides guidance on the determination of the measurement date for transactions that are within the scope of this Subtopic.
Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised.
Pursuant to ASC paragraph 505-50-30-S99-1, if the Company receives a right to receive future services in exchange for unvested, forfeitable equity instruments, those equity instruments are treated as unissued for accounting purposes until the future services are received (that is, the instruments are not considered issued until they vest). Consequently, there would be no recognition at the measurement date and no entry should be recorded.
Income Tax Provision
The Company follows paragraph 740-10-30-2 of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date.
The Company adopted the provisions of paragraph 740-10-25-13 of the FASB Accounting Standards Codification. Paragraph 740-10-25-13.addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under paragraph 740-10-25-13, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Paragraph 740-10-25-13 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no material adjustments to its liabilities for unrecognized income tax benefits according to the provisions of paragraph 740-10-25-13.
The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying consolidated balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its consolidated balance sheets and provides valuation allowances as management deems necessary.
Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.
Uncertain Tax Positions
The Company did not take any uncertain tax positions and had no adjustments to its income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the reporting period ended May 31, 2014 or 2013.
- 39 -
Net Income (Loss) per Common Share
Net income (loss) per common share is computed pursuant to paragraph of 260-10-45-10 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options and warrants.
The following table shows number of potentially outstanding dilutive shares excluded from the diluted net income (loss) per share calculation as they were anti-dilutive:
Cash Flows Reporting
The Company has adopted paragraph 230-10-45-24 of the FASB Accounting Standards Codification for cash flows reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-24 of the FASB Accounting Standards Codification to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments.
Subsequent Events
The Company follows the guidance in Section 855-10-50 of the FASB Accounting Standards Codification for the disclosure of subsequent events. The Company will evaluate subsequent events through the date when the financial statements were issued. Pursuant to ASU 2010-09 of the FASB Accounting Standards Codification, the Company as an SEC filer considers its financial statements issued when they are widely distributed to users, such as through filing them on EDGAR.
- 40 -
Recently Issued Accounting Pronouncements
In April 2014, the FASB issued ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this Update change the requirements for reporting discontinued operations in Subtopic 205-20.
Under the new guidance, a discontinued operation is defined as a disposal of a component or group of components that is disposed of or is classified as held for sale and “represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results.” The ASU states that a strategic shift could include a disposal of (i) a major geographical area of operations, (ii) a major line of business, (iii) a major equity method investment, or (iv) other major parts of an entity. Although “major” is not defined, the standard provides examples of when a disposal qualifies as a discontinued operation.
The ASU also requires additional disclosures about discontinued operations that will provide more information about the assets, liabilities, income and expenses of discontinued operations. In addition, the ASU requires disclosure of the pre-tax profit or loss attributable to a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation in the financial statements.
The ASU is effective for public business entities for annual periods beginning on or after December 15, 2014, and interim periods within those years.
In May 2014, the FASB issued the FASB Accounting Standards Update No. 2014-09 “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”).
This guidance amends the existing FASB Accounting Standards Codification, creating a new Topic 606, Revenue from Contracts with Customer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.
To achieve that core principle, an entity should apply the following steps:
1.
Identify the contract(s) with the customer
2.
Identify the performance obligations in the contract
3.
Determine the transaction price
4.
Allocate the transaction price to the performance obligations in the contract
5.
Recognize revenue when (or as) the entity satisfies a performance obligations
The ASU also provides guidance on disclosures that should be provided to enable financial statement users to understand the nature, amount, timing, and uncertainty of revenue recognition and cash flows arising from contracts with customers. Qualitative and quantitative information is required about the following:
1.
Contracts with customers - including revenue and impairments recognized, disaggregation of revenue, and information about contract balances and performance obligations (including the transaction price allocated to the remaining performance obligations)
2.
Significant judgments and changes in judgments - determining the timing of satisfaction of performance obligations (over time or at a point in time), and determining the transaction price and amounts allocated to performance obligations
3.
Assets recognized from the costs to obtain or fulfill a contract.
ASU 2014-09 is effective for periods beginning after December 15, 2016, including interim reporting periods within that reporting period for all public entities. Early application is not permitted.
In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation.
The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in
- 41 -
which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments.
The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify U.S. GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage.
The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
The company has limited operations and is considered to be in the development stage. The Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. The adoption of this ASU allows the company to remove the inception to date information and all references to development stage.
In June 2014, the FASB issued the FASB Accounting Standards Update No. 2014-12 “Compensation-Stock Compensation (Topic 718) : Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”).
The amendments clarify the proper method of accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period. The Update requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered.
The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted.
In August 2014, the FASB issued the FASB Accounting Standards Update No. 2014-15 “Presentation of Financial Statements- Going Concern (Subtopic 205-40) (Topic 718): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”).
The Update provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes.
This Update is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures.
The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2016. Earlier adoption is permitted.
Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements
- 42 -
Note 3 - Going Concern
The financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.
As reflected in the financial statements, the Company had a deficit accumulated at May 31, 2014 and had a net loss and net cash used in operating activities for the reporting period then ended. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The Company is attempting to commence operations and generate revenue; however, the Company’s cash position may not be sufficient to support its daily operations. While the Company believes in the viability of its strategy to generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds.
The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Note 4 - Exclusive Technology License
On September 3, 2007 (“Effective Date”), the Company acquired an exclusive technology license (“Agreement”) for the Territory of North America, comprising Canada, the United States and Mexico to manufacture or assemble and market the AO-System water treatment system (AO - Anodic Oxidation) from Hydrosystemtechnik, GmbH (“Grantor”), a German corporation. The Company has agreed to pay a licensing fee as follows: (i) 10,000 (equivalent to $13,635 at September 3, 2007) within 120 days of the Effective Date; (ii) 20,000 (equivalent to $27,270 at September 3, 2007) on November 30, 2008; and (iii) 20,000 (equivalent to $27,270 at September 3, 2007) upon AO-System being certified and approved by the United States Environmental Protection Agency (“EPA”) for selling on a commercial basis in the United States, or 50,000 (equivalent to $68,175 at September 3, 2007) in aggregate, all of which are non-refundable and may be recouped from the future Product Royalty in perpetuity at ten percent (10%) of the Net Selling Price on all AO water treatment systems assembled or manufactured by the Company or a subcontract manufacture utilized by the Company and paid for by customers of the Company due and payable quarterly within 30 days from the last day of the quarter provided the Company exercises its right to manufacture or assemble AO-Systems. In the event the Company does not manufacture or assemble AO-Systems, the Company pays no royalty on finished units purchased from the licensor and resold to customers of the Company, the license fees will no longer be considered prepaid royalties and the Company will amortize prepaid royalties over the remaining legal life of the patent of AO System, or estimated useful life, or the term of the contract, whichever is shorter in the event that the Company decides not to manufacture or assemble AO-System.
The Company’s exclusive license right to sell finished AO Units in the territory is contingent upon the Company achieving minimum annual sales volume as defined in Table 1 of Appendix B of this Agreement among other terms and conditions at the end of each business year, beginning with the third (3rd) anniversary after the effective date of this Agreement. In the event the objectives defined in years three (3) through five (5) of Table 1 in Appendix B are not attained at the end of each business year, this agreement shall, at the option of the GRANTOR, automatically revert to a non-exclusive marketing agreement and the Company will no longer have the right in manufacturing or assembling of AO Systems.
The Company determined that the (iii) payment required under the exclusive license agreement upon approval of U.S. EPA is a contractual liability instead of contingent liability as the AO system has been certified and approved by the European Union for selling on a commercial basis in Europe and the United States Environmental Protection Agency’s certification and approval for selling on a commercial basis in the United States is a matter of procedure and recorded deferred license fees and related license fees payable of $68,175, 50,000 measured in U.S. Dollar at September 3, 2007, the transaction date upon signing of the Exclusive License Agreement.
The Company paid the first installment of 10,000 with $14,892 on December 17, 2007 and the second installment of 20,000 due on November 30, 2008 was paid with $26,486 on January 26, 2009. The due date for the third installment of 20,000 is undeterminable pending on EPA approval.
The Company determined that since it is currently unable to secure EPA approval of the AO-System in order to begin selling in the United States within the time period specified in the agreement, the agreement has reverted to a non-exclusive
- 43 -
marketing agreement. Consequently, the Company impaired the entire balance of $68,175 of the deferred licensing fee on June 30, 2010.
Note 5 - Stockholders’ Deficit
Shares Authorized
Upon formation the aggregate number of shares which the Company shall have authority to issue is eighty million (80,000,000) shares, consisting of two classes to be designated, respectively, “Common Stock” and “Preferred Stock,” with all of such shares having a par value of $.001 per share. The total number of shares of Preferred Stock that the Company shall have authority to issue is five million (5,000,000) shares. The total number of shares of Common Stock that the Company shall have authority to issue is seventy five million (75,000,000) shares.
Common Stock
The Company was incorporated on May 12, 2006. In May 2006, 200,000 shares of its common stock were sold to the Company’s founder and President at $0.01 per share for $2,000 in cash.
During the fiscal year ended June 30, 2007, the Company sold 300,000 shares of its common stock to the Company’s founder and President at $0.01 per share for $3,000 in cash.
During the fiscal year ended June 30, 2008, the Company sold 1,000,000 shares of its common stock at $0.10 per share for $100,000 in cash.
On November 25, 2008, the Company’s Board of Directors authorized a Regulation D, Rule 504 stock sale and entered into a definitive agreement relating to the private placement of $7,500 of its securities through the sale of 15,000 shares of its common stock at $0.50 per share inclusive of a stock warrant to purchase 15,000 shares of its common stock exercisable at $1.00 expiring three (3) years from the date of issuance with Ryan Edington, the brother of Jerod Edington, the Vice-president and Chief Operating Officer of the Company. The fair value of these warrants granted, estimated on the date of grant, was $3,300, which has been recorded as additional paid-in capital, using the Black-Scholes option-pricing model with the following weighted-average assumptions:
On January 23, 2009, the Company sold 250,000 shares of its common stock at $0.20 per share to Ron Kunisaki, the then president of the company, for $50,000 in cash.
On July 25, 2009, pursuant to the Bridge Loan Agreement entered into by an entity and Hydrodynex, Inc., dated July 24, 2008, Triax Capital Management exercised the conversion rights of the promissory note at the agreed rate of $0.25 per share. The original loan to the Company was in the amount of $4,000, and the 365 days of interest at 8% per annum of $320, equates to a conversion value of 17,280 shares.
On August 23, 2009, pursuant to the Bridge Loan Agreement entered into by a non-affiliated individual and Hydrodynex, Inc., dated August 22, 2008, the loaner exercised the conversion rights of the promissory note at the agreed rate of $0.25 per share. The original loan to the Company was in the amount of $5,000, and the 365 days of interest at 8% per annum of $400, equates to a conversion value of 21,600 shares.
On September 26, 2009, the Company sold 30,000 shares of common stock at $0.25 per share for $7,500 in cash.
On November 9, 2009, the Company sold 140,000 shares of common stock at $0.25 per share for $35,000 in cash.
- 44 -
On September 30, 2011, the Company converted $16,300 in advances from an officer into 326,000 shares of common stock at $0.05 per share.
On September 30, 2011, the Chief Operating Officer of the company forgave a debt of $275 which was recorded as additional paid in capital.
On August 30, 2013, two creditors of the Company converted their loans due in the aggregate of $27,250 into common shares of the Company at $0.05 per share. A total of 545,000 shares were issued in exchange for the loans.
On January 31, 2014, the Company entered into a definitive agreement relating to the private placement of $3,000 of its securities through the sale of 30,000 shares of its common stock at $0.10 per share to an investor.
Stock Option Plan
On May 19, 2006, the Company’s board of directors approved the adoption of the “2006 Non-Qualified Stock Option and Stock Appreciation Rights Plan” (“2006 Plan”) by unanimous consent. The 2006 Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 1,000,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises.
There are no outstanding and exercisable stock options as of May 31, 2014:
As of May 31, 2014, there were 1,000,000 shares remaining available for issuance under the 2006 Plan.
Warrants
(i) Warrants issued in 2011
On September 30, 2011, the Company converted $37,600 in accrued expenses - officer into warrants to purchase 752,000 shares of its common stock exercisable at $0.01 per share and expiring three (3) years from the date of issuance. The Company valued these warrants issued at $30,080 on the date of grant using the Black-Scholes Option Pricing Model, and recorded both (i) the fair value of warrants of $30,080 and (ii) the difference between the fair value of warrants and accrued expenses - officer, the forgiveness of debt from officer of $7,520 as additional paid-in capital.
On September 30, 2011, the Company converted $8,385 in accounts payable into warrants to purchase 167,700 shares of its common stock exercisable at $0.01 per share, expiring thee (3) years from the date of issuance. The Company valued these warrants issued at $6,708 on the date of grant using the Black-Scholes Option Pricing Model, and recorded (1) the fair value of warrants of $6,708 as additional paid-in capital and (2) the difference between the fair value of warrants and accounts payable of $1,677 forgiveness of debt.
The fair value of each warrant grant estimated on the date of grant uses the Black-Scholes option-pricing model with the following assumptions:
- 45 -
The table below summarizes the Company’s warrants activity though May 31, 2014:
The following table summarizes information concerning outstanding and exercisable warrants as of May 31, 2014:
Note 6 - Related Party Transactions
Advances from Officer
On October 11, 2011, the Chief Executive Officer of the Company advanced the Company $2,000 with no interest and an extended maturity date to June 30, 2013. $200 of this advance was paid back on November 9, 2012.
On February 17, 2012, a related party of the Company advanced the Company $5,000 with no interest and a maturity date of June 30, 2012, which was subsequently extended to December 31, 2013.
On April 3, 2012, the Chief Executive Officer of the Company advanced the Company $10,000 with no interest and an extended maturity date to December 31, 2013.
On December 28, 2012, the Chief Executive Officer of the Company advanced the Company $1,000 with no interest and a maturity date of December 31, 2013.
On January 22, 2013, $500 was repaid on the advances due to the Chief Executive Officer.
On February 12, 2013, the Chief Executive Officer of the Company advanced the Company $2,000 with no interest and a maturity date of December 31, 2013.
- 46 -
On May 9, 2013, the Chief Executive Officer of the Company advanced the Company $5,600 with no interest and a maturity date of December 31, 2013.
On May 17, 2013, the Chief Executive Officer of the Company advanced the Company $300 with no interest and a maturity date of December 31, 2013.
On May 29, 2013, a related party of the Company advanced the Company $2,000 with no interest and a maturity date of December 31, 2013. On August 30, 2013, the advance was satisfied.
On August 30, 2013, the Company issued 545,000 unregistered shares of its common stock, par value $0.001, at $0.05 per share to two creditors in exchange for aforementioned outstanding loans in aggregate of $27,250 and aggregate interest accrued of $0. A total of 405,000 shares were issued to affiliate Jerod Edington, Officer and Director of the Company, in exchange for the loans due to him. A total of 140,000 shares were issued to a related party in exchange for the loans due to it.
Notes Payable - Officer
On September 20, 2013, the Chief Executive Officer of the Company advanced the Company $1,000 with no interest and a maturity date of September 20, 2014.
On October 23, 2013, the Chief Executive Officer of the Company advanced the Company $2,000 with no interest and a maturity date of October 23, 2014.
On April 19, 2014, the Chief Executive Officer of the Company advanced the Company $3,000 for a term of one year at 0% interest.
Free Office Space from Its Stockholder and Chief Operating Officer
The Company has been provided office space by its stockholder and Chief Executive Officer at no cost. The management determined that such cost is nominal and did not recognize the rent expense in its financial statements.
Note 7 - Income Tax Provision
Deferred Tax Assets
At May 31, 2014, the Company had net operating loss (“NOL”) carry-forwards for Federal income tax purposes of $353,971 that may be offset against future taxable income through 2033. No tax benefit has been reported with respect to these net operating loss carry-forwards in the accompanying financial statements because the Company believes that the realization of the Company’s net deferred tax assets of approximately $120,350, was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are offset by a full valuation allowance.
Deferred tax assets consist primarily of the tax effect of NOL carry-forwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding its realizability. The valuation allowance increased approximately $3,573 and $5,310 for the 12 months ended May 31, 2014 and 11 months ended May 31, 2013, respectively.
Components of deferred tax assets are as follows:
Income Tax Provision in the Statements of Operations
- 47 -
A reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes is as follows:
Note 8 - Subsequent Events
The Company has evaluated all events that occur after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The Management of the Company determined that there were certain reportable subsequent events to be disclosed as follows:
On June 18, 2014, the Company entered into a definitive Sixty (60) day Option to Purchase Assets Agreement to purchase all of the assets of Zoydan Games, Inc (“Zoydan”), a private company organized in the state of Washington on July 8, 2011. The agreement calls for this issuance of Forty Two Million (42,000,000) shares of restricted common stock to be issued to Zoydan Games, Inc. (“Zoydan”), which will be exchanged for specific assets of Zoydan and subsequently disbursed to the existing shareholders of Zoydan. Zoydan Games, Inc. was organized as a card and board game design, development, publishing and specialty marketing company. The acquisition of the assets of Zoydan will be subject to a future vote of the shareholders of the Company pursuant to a special meeting of the shareholders.
On July 24, 2014, the Company and Zoydan agreed to extend the option date to September 15, 2014.
On August 8, 2014, the Chief Executive Officer of the Company advanced the Company $500 for a term of one year at 0% interest.
- 48 -
ITEM 9.
ITEM 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure
None.
ITEM 9A
ITEM 9A Controls and Procedures
Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, a company’s principal executive and principal financial officers and effected by a company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
- Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;
- Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of May 31, 2014. We identified a material weakness in our internal control over financial reporting as of May 31, 2014 because fundamental elements of an effective control environment were not present as of May 31, 2014, including independent oversight and review of financial reporting, the financial reporting processes and procedures, and internal control procedures by our board of directors as we have not established an audit committee and our full board has not been adequately performing those functions. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. There exists a nearly complete overlap between management and our board of directors, with four of our four directors being members of management. Specifically, we do not currently have the ability to objectively monitor the processes and procedures of financial reporting as the individuals responsible for financial reporting also comprise all but one of the members of our board of directors. Additionally, due to insufficient staffing and lack of full-time personnel, it has not been possible to ensure appropriate segregation of duties between incompatible functions and formalized monitoring procedures have not, to date, been established or implemented. In the course of our assessment, we also identified that there were control deficiencies which were the result of our not maintaining a sufficient complement of personnel to ensure that financial information (both routine and non-routine) is adequately analyzed and reviewed on a timely basis to detect misstatements. Essentially, the material weaknesses we have identified in our assessment are the same as those identified in our assessment as of May 31, 2013. Due to a lack of sufficient capital resources and our lack of independent outside directors, we have been unable to remedy the material weaknesses which existed last year.
Based on this assessment and the material weakness described above, management has concluded that internal control over financial reporting was not effective as of May 31, 2014.
This annual report does not include an attestation report of the company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the company to provide only management’s report in this annual report.
We intend to take the following steps as soon as practicable to remediate the material weakness we identified as follows:
- We will segregate incompatible functions using existing personnel where possible or, given sufficient capital resources, we will hire additional personnel to perform those functions.
- To the extent we can attract outside directors, we will increase the oversight and review procedures of our board of directors with regard to financial reporting, financial reporting processes and procedures and internal control procedures.
- To the extent we can attract outside directors, we will nominate an audit committee to review and assist the board with its oversight responsibilities.
- 49 -
Changes In Internal Control Over Financial Reporting
As of the end of the period covered by this report, there have been no changes in internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) during the year ended May 31, 2014, that materially affected, or are reasonably likely to materially affect, our company’s internal control over financial reporting.
ITEM 9B
ITEM 9B Other Information
None.
PART III
ITEM 10.
ITEM 10. Directors, Executive Officers and Corporate Governance
A. Directors, Executive Officers, Promoters and Control Persons
Our current executive officer, director and significant employee of Hydrodynex is as follows:
Name
Age
Position
Jerod Edington
President, Chief Executive Officer, Chief Financial Officer, Chief Operating Officer
Vice President, Treasurer, Secretary, & Director
Each director is elected to hold office for a one year term or until the next annual meeting of stockholders and until his successor is elected and qualified. The officers of Hydrodynex serve at the pleasure of Hydrodynex’ Board of Directors.
The following sets forth certain biographical information with respect to the director and executive officer of Hydrodynex.
Jerod Edington - Founder, President, Chief Executive Officer, Chief Financial Officer, Chief Operating Officer Vice President, Treasurer, Secretary, & Director. Mr. Edington attended the University of Washington in Seattle, Washington. He earned a B.S. in Zoology in 2000 and did radiation cancer and tumor research at the University of Washington Medical Center’s Radiation Oncology Dept. From 2000 until 2007 he worked in the TV/Film Production business as a professional actor and occasional producer. He is a member of the Screen Actors Guild Union. Mr. Edington has served as the CEO and various other officer positions in Hydrodynex, Inc., a commercial scale water disinfection technology company from May of 2006 until the present. He has been a capital formation consultant and business development consultant in the mergers and acquisition industry since September of 2009 where he has worked on projects involving oil & gas, precious metals and mining, pharmaceuticals, and various technologies.
There are no family relationships between any of the directors and executive officers.
Involvement in Certain Legal Proceedings
To our knowledge, during the past ten years, no present director or executive officer of our company: (1) filed a petition under the federal bankruptcy laws or any state insolvency law, nor had a receiver, fiscal agent, or similar officer appointed by a court for the business or present of such a person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer within two years before the time of such filing; (2) was convicted in a criminal proceeding or named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting the following activities: (i) acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, associated person of any of the foregoing, or as an investment advisor, underwriter, broker or dealer in securities, or as an affiliated person, director of any investment company, or engaging in or continuing any conduct or practice in connection with such activity; (ii) engaging in any type of business practice; (iii) engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or federal commodity laws; (4) was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or state authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described above under this Item, or to be associated with persons engaged in any such activity; (5) was found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission to have violated any federal or state securities law
- 50 -
and the judgment was not subsequently reversed, suspended or vacated; (6) was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated.
B. Section 16(a) Beneficial Ownership Reporting Compliance.
Section 16(a) of the Securities Exchange Act of 1934 requires our directors and executive officers, and persons who own more than ten percent of our common stock, to file with the Securities and Exchange Commission initial reports of ownership and reports of changes of ownership of our common stock. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file. We have no knowledge that, as of the date of this filing, our directors, executive officers, and persons who own more than ten percent of our common stock, have not filed a required Form 3 initial report, Form 4 current report, or an annual Form 5.
Code of Ethics
On August 15, 2008, we adopted a Code of Business Conduct and Ethics for Directors, Officers and Employees and a Code of Ethics for the Chief Executive Officer and Senior Financial Officers. Both are exhibits to this Report on Form 10-K. We will provide to any person, without charge, upon request, a copy of our Code of Business Conduct and Ethics for Directors, Officers and Employees and a Code of Ethics for the Chief Executive Officer and Senior Financial Officers. Any person may make such a request by mailing such a request addressed to our President, Jerod Edington, at the address of our executive offices at 451 W. 21st Ave., Spokane, WA 99203.
Audit Committee and Audit Committee Financial Expert
We are not a “listed company” under SEC rules and are therefore not required to have an audit committee comprised of independent directors. As we are a development stage company with minimal revenues from operations, few employees, and relatively simple financial statements, as of May 31, 2014 we had not constituted any board committees, including an audit committee. On August 15, 2008, we adopted charters for an Audit Committee, a Compensation Committee, and a Corporate Governance and Directors Nominating Committee, but will not have these committees until we have the resources to do so. We do not have an audit committee financial expert who is an outside director. As our business grows and our financial statements become more complicated, we intend to seek an outside director who can qualify as an audit committee financial expert.
ITEM 11.
ITEM 11. Executive Compensation.
A. Summary Compensation Table
The table below sets forth the aggregate annual and long-term compensation paid by us during the twelve months ended May 31, 2014 and eleven months ended May 31, 2013 to our Chief Executive Officer, Jerod Edington, and former Chief Executive Officer, Ronald Kunisaki, who served as our President and Chief Executive Officer from February 6, 2009 to June 3, 2013 (the “Named Executive Officer”). No executive officer’s salary and bonus exceeded $100,000 for the twelve months ended May 31, 2024 or eleven months ended May 31, 2013.
- 51 -
B. Narrative Disclosure to Summary Compensation Table
Former officer and director Ronald Kunisaki had not entered into a formal written employment agreement with Hydrodynex and has not been compensated in any manner to date for his service as our President and CEO since his appointment in February 2009. Officer and director Jerod Edington had not entered into a formal written employment agreement with Hydrodynex and has not been compensated in any manner for his service as our President and CEO since his appointment in June 6, 2013.
C. Outstanding Equity Awards at Fiscal Year End
No stock options are currently outstanding as of May 31, 2014.
D. Compensation of Directors
No compensation was paid to directors for their director services during the year ending May 31, 2014.
ITEM 12.
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The following table sets forth, as of September 15, 2014 certain information with respect to the beneficial ownership of our common stock by each stockholder known by us to be the beneficial owner of more than 5% of our common stock and by each of our current directors and executive officers. The percentage of shares beneficially owned is based on 2,874,880 shares of common stock outstanding as of September 15, 2014. Shares of common stock subject to stock options and warrants that are currently exercisable or exercisable within 60 days of September 15, 2014, are deemed to be outstanding for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Each person has sole voting and investment power with respect to the shares of common stock, except as otherwise indicated. Beneficial ownership consists of a direct interest in the shares of common stock, except as otherwise indicated. Except as otherwise listed below, the address of each person is 451 W. 21st Ave. Spokane, WA 99203.
(1)
Jerod Edington- The holdings of Mr. Edington include 1,231,000 shares of common stock, warrants to purchase 752,000 shares at $.01 per share that are exercisable currently or within 60 days of September 15, 2014.
(2)
Ronald Kunisaki- The holdings of Ronald Kunisaki include 250,000 shares of common stock
(3)
Marycliff Investment Corp- The holdings of Marycliff investment Corp. include 170,000 shares of common stock. Sherry Edington, mother of officer and director Jerod Edington, has voting power of this entity.
(4)
The holdings of the executive officers and directors as a group include an aggregate of 1,231,000 shares of common stock and 752,000 shares at $.01 per share that are exercisable currently or within 60 days of September 30, 2013.
Equity Compensation Plan Information
The following table sets forth information about the common stock available for issuance under compensatory plans and arrangements as of May 31, 2014:
- 52 -
ITEM 13.
ITEM 13. Certain Relationships and Related Transactions, and Director Independence.
On September 30, 2011, we converted $16,300 in loans from officer and director, Jerod Edington, into restricted common shares of Hydrodynex at $0.05 per share. A total of 326,000 shares were issued in this transaction.
On September 30, 2011, we converted $37,600 in accrued consulting fees owed to officer and director, Jerod Edington, into 752,000 three-year warrants, where one warrant entitles to purchase one share of our restricted common stock at an exercise price of $0.01 per share.
On September 30, 2011, officer and director, Jerod Edington, forgave a debt of $275 to Hydrodynex for no consideration.
On October 11, 2011, an officer and director, Jerod Edington, loaned Hydrodynex $2,000 to be reimbursed by June 30, 2013 with no interest due and was unsecured.
On April 3, 2012, an officer and director, Jerod Edington, loaned Hydrodynex $10,000 to be reimbursed by June 30, 2013 with no interest due and was unsecured. This due date was extended to December 31, 2013.
On December 28, 2012, officer and director, Jerod Edington, advanced the Company $1,000 with no interest and a maturity date of December 31, 2013.
On January 22, 2013, $500 was repaid on the advances due to officer and director, Jerod Edington.
On February 12, 2013, officer and director, Jerod Edington, advanced the Company $2,000 with no interest and a maturity date of December 31, 2013.
On May 9, 2013, officer and director, Jerod Edington, advanced the Company $5,600 with no interest and a maturity date of December 31, 2013.
On May 17, 2013, officer and director, Jerod Edington, advanced the Company $300 with no interest and a maturity date of December 31, 2013.
On May 29, 2013, a related party of the Company advanced the Company $2,000 with no interest and a maturity date of December 31, 2013.
On August 30, 2013, the Company issued 545,000 unregistered shares of its common stock, par value $0.001, at $0.05 per share to two creditors in exchange for aforementioned outstanding loans in aggregate of $27,250 and aggregate
- 53 -
interest accrued of $0. A total of 405,000 shares were issued to affiliate Jerod Edington, Officer and Director of the Company, in exchange for the loans due to him. A total of 140,000 shares were issued to a related party in exchange for the loans due to it.
On April 19, 2014, the Chief Executive Officer of the Company advanced the Company $3,000 for a term of one year at 0% interest.
On August 8, 2014, the Chief Executive Officer of the Company advanced the Company $500 for a term of one year at 0% interest.
Director Independence
The Board of Directors has determined that its one member is not currently an “independent director” as that term is defined in Rule 4200(a)(15 ) of the Marketplace Rules of the National Association of Securities Dealers. We are not presently required to have independent directors. If we ever become a listed issuer whose securities are listed on a national securities exchange or on an automated inter-dealer quotation system of a national securities association, which has independent director requirements, we intend to comply with all applicable requirements relating to director independence.
ITEM 14.
ITEM 14. Principal Accounting Fees and Services.
The aggregate fees billed by our principal accountant for services rendered during the twelve months ended May 31, 2014 and the eleven months ended May 31, 2013 are set forth in the table below:
(1)
“Audit fees” consists of fees incurred for professional services rendered for the audit of annual financial statements, for reviews of interim financial statements included in our quarterly reports on Form 10-Q, and for services that are normally provided in connection with statutory and regulatory filings or engagements.
(2)
“Audit-related fees” consists of fees billed for professional services that are reasonably related to the performance of the audit or review of our financial statements, but are not reported under “Audit fees.”
(3)
“Tax fees” consists of fees billed for professional services relating to tax compliance, tax advice and tax planning.
(4)
“All other fees” consists of fees billed for all other services, such as review of our registration statement on Form S-1 and EDGAR filing expenses.
Audit Committee’s Pre-Approval Policies and Procedures
We do not at this time have an audit committee. Our Board of Directors (in lieu of an audit committee) pre-approves the engagement of our principal independent accountants to provide audit and non-audit services Section 10A(i) of the Securities Exchange Act of 1934 prohibits our auditors from performing audit services for us as well as any services not considered to be “audit services” unless such services are pre-approved by the Board of Directors (in lieu of an audit committee) or unless the services meet certain de minimus standards.
- 54 -
PART IV
ITEM 15.
ITEM 15. Exhibits, Financial Statement Schedules.
(a) 1 & 2.
Financial Statements See Item 8 in Part II of this report.
All other financial statement schedules are omitted because the information required to be set forth therein is not applicable or because that information is in the financial statements or notes thereto.
(a) 3.
Exhibits specified by item 601 of Regulation S-B.
INDEX TO EXHIBITS
- 55 -
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act of 1934, as amended, the registrant caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, on this 15th day of September, 2014.
In accordance with Section 13 or 15(d) of the Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant in the capacities indicated below on this 15th day of September, 2014.
Signature
Title
/s/ Jerod Edington
Director, CEO, CFO, COO, President, VP, Treasurer, Secretary
Jerod Edington
- 56 -